

Mr. Benoit Battistelli (personnellement)  
Directeur General, Institut National  
de la Propriété Industrielle  
Paris 8e

Y. Zagzansky, Entraide, 22 rue Ste  
Marthe, 75010 Paris  
Paris, le 22 Juin 2004  
APPLICATION N°03-08880

INPI PARIS 34 SP

22 JUIN 2004

Cher Monsieur le Directeur Général d'Institut National, Ça va vers gigantesque explosion! Il peut déjà  
sembler que tout le Monde peut faire le crime ordonné sans aucune peur. Et je "felicite" les auteurs  
(logiquement de Département français, TRES malheureusement) de "rien dire" avec ces applications  
d'une seulement "petite misère" dans ocean de grand crime! logiquement TOUT ORGANISÉ en unisson:  
comme TOUT EST COUVERT, TOUT EST PERMI: Directeur Général d'Organisation Mondiale de la  
Propriété Industrielle Kamil Idris apparaît comme criminel contre Humanité ouvert déclaré DANS  
OUVERTEMENT EVIDENT (sur le même ordre comme fameux Assassin Connu Joseph Désiré  
MOBUTU??). Je vous demontre la documentation de trop accablant par primitivité des hautes  
mensonges logiques vers Crime contre Humanité. On est bien sauvé pour le moment en voyant  
seulement dans le sable. Je vous prie de croire, Cher Monsieur, à l'expression de mes sentiments  
distingués. Dr.Y.Zagzansky

distingués. Dr.Y.Zagzansky

*Y. Zagzansky*

PCT  
COMMUNICATION IN CASES FOR WHICH  
NO OTHER FORM IS APPLICABLE

Date of mailing (day/month/year) 28 July 2003 (28.07.03)	
Applicant's or agent's file reference PCT/EP02/02302	REPLY DUE see paragraph 1 below
International application No. PCT/EP02/02302	International filing date (day/month/year) 04 March 2002 (04.03.02)
Applicant ZAGZANSKY, Yuly	
1. <input type="checkbox"/> REPLY DUE within _____ month/days from the above date of mailing <input checked="" type="checkbox"/> NO REPLY DUE, however, see below <input type="checkbox"/> IMPORTANT COMMUNICATION <input checked="" type="checkbox"/> INFORMATION ONLY	
2. COMMUNICATION: <p>The International Bureau acknowledges receipt on 29 May 2004 (29.05.04) of your facsimile letter concerning the above identified international application. Unfortunately, as already indicated in Form PCT/IB/345 of 28 July 2003 (28.07.03), the International Bureau is not in a position to be of help in this matter as the International Bureau is not the competent Authority for international search matters.</p> <p>Therefore, your letter has only been recorded but no action has been taken by the International Bureau.</p>	
The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 26, Switzerland Facsimile No. (41-22) 338.89.73	Authorized officer Margaret GODBERSEN (Fax 338 8975) Telephone No. (41-22) 338.91.28

Form PCT/IB/345 (July 1992)

Fax: 41-22-740-14-35 VERY URGENT! For Dossier of Appl. PCT/EP02/02302 "End of AIDS for General  
Virology, based on profound science as protein folding; safe vaccines, universal antimicrobial means,  
mad cow and".

Mr. Kamel Idris (personally) Dr.Y.Zagzansky, Entraide, 22 rue Ste Marthe 75010 Paris  
General Director of World International Paris, 28th May 2004  
Patent Organization, Geneva

**WITHOUT DOUBT UNLAWFUL, ISA "SEARCH", MADE AS INTENTIONAL CRIMINAL SABOTAGE OF PCT  
CONVENTION, NOT ACCORDING TO PCT LAW, BUT FORMALLY OPENLY OPPOSITELY, MUST BE  
CANCELED BY SUPERVISING (Art.1(1), 51(1) WIPO; DISCIPLINARY PENALTY CRIME OF INTENTIONAL  
SABOTAGE, IGNORING PCT CONVENTION) MUST BE DONE TOO.**

Dear General Director! Demonstrating complete absence of law, Governmental EPO made "Search"  
Oppositely to written law for this Medicinal Application of century with end of AIDS, cancer, mad cow etc.  
Since June 03, with help of Mrs. M. Goddensen (IB), I received (03/09/03) finally letter without any (of  
course) concrete explanation of simple sabotage with intentional falsified half of signature from  
Director 1521 EPO Search (see below) (who must be judged for this anyway!). In spite of my clear evident  
answer I had no any answer neither from EPO, nor from WIPO during very long time. Only, justly in  
writing this letter, I received (26.05.04), very strange letter of EPO Vice-Director, again without impossible  
explanation only because it is evidently impossible as anyone will surprise by simplicity of excess of  
arbitrary from below:

\$1. Simply oppositely to ignored PCT Convention (cited by EPO, Rule 39(i) PCT), EPO does not  
search claims 1, 2, 6 and 10 "as scientific theories" in knowing that this Rule obliges to make this Search  
according to PCT Guidelines (§9.05 in reference to this Rule!): "When viewing claims as a whole, if  
theories are applied or implemented to produce a practical application or to have technical character,  
search is required". Consequently, partial "Search" of sole claim 3, made without claims 1 and 2 is null  
and this SEARCH DOES NOT EXIST AT ALL!

\$2. Directly oppositely to ignored law, EPO does not search claims 4, 5, 7-9, 11, 12 as generally for  
"large number of possible compounds" for use in therapy method. But directly according to law (cited in  
all these claims Art.52(4)). In EPC (itself) (Art.52), there are specially given references, obliging  
EPO to make search of the process of therapeutic method for being new and inventive with always given  
by me examples of substances for manufacture of such medicaments. It is too primitive sabotage in  
Medicine (AIDS, cancer, mad cow) based on processes "upon living things" ("PCT Guidelines" §5.12).  
Moreover, Search of above claims must be done with basic scientific theories (§1) as a whole (Rule 39(i)  
PCT).

\$3. And the above (§1, 2) was "the reason" of demonstrative sabotage of all Search! and, of course (see  
also §5), of cynic absence of impossible explanations. But "problem" became urgent: I must enter in  
many National stages without Search (instead of best Search for XXI century preparations) due to only  
demonstrative sabotage to Search oppositely to PCT against Initial PCT Request!

\$4. UP TO EPO: EPO is obliged to do this Urgent Search (a) with original text (even with better!)  
claim(s) or (b) with text certainly insignificantly modified (for EPO, too) or (c) with original and after this  
with little modified text: UP TO EPO: it is not TOO PRIMITIVE obstacle and EPO asked nothing else  
during "Search" (§1).

\$5. EPO responsible persons (Chief of Unity and Vice-President) wrote that "there is no provision  
for review or appeal" at International phase. It is too simple open misinformation. EPO must, in carrying  
out International Search, be guided by the PCT Search Guidelines ("EPO Guidelines §BIII-4.4, "Case Law  
of Boards of Appeal of EPO" §IX.C.1.). And these Guidelines obliges EPO (§1.04): "Re-view of action of  
the Authority (ISA) should take place when "such review is provided for under the applicable national law  
and practice". Wherein National EPO law stipulates: "Any decision of departments of the EPO are subject  
to review before a Board of Appeal" ("EPO Guidelines" General Introduction §3.2). Independently DE  
FACTO, it is ALSO directly confirmed by EPO Law ("Case Law", p.574): "There is no obstacle to making  
use of appeal procedures provided for under the EPC to supplement the provisions of the PCT" (with  
EPO as Designated Office too). Moreover, "all (according to EPO: EPO is 100% included!) PCT authorities  
in fact accept and duly consider any request for reconsideration" ("Case Law", p.574).  
But MOREOVER, the given EPO misinformation a priori CANNOT take place! With the same obvious §1,  
(both pages are signed) *Y. Zagzansky*

2. at the same good text and THE SAME very good claims. EPO National phase must have good complete Search (as  
with any other good Application even with OBJECTIVE EPO errors) without additional payment. So by  
criminal intentional sabotage, I MUST lose International Search for all countries (without any my  
fault!!!!), that will be good only at EPO National stage. It is impossible and incredible a priori, that is  
confirmed by above LAW!

But moreover, at intentional penal Totalitarian, Ignoring PCT Convention (it means of Request! and  
WIPO must immediately stop the Ignoring of PCT Law) (§1.21), the Disciplinary Board of Appeal ("Law  
case" VIII-3.1.) punishes such penal crime too: "As such these provisions ("European Convention of  
Protection of Human Rights") should be considered part of the legal system of this Organization (EPO)  
and should be observed by all its departments" (wherein "penalty" must be "proportionate to the  
seriousness of the charges" - millions of euros and Crime against Humanity, justly).

SO THE "PROBLEM" IS ONLY IN §1 and 2, that are too obvious formally. And justly the EPO  
SPECIALISTS EXPRESSLY do not discuss it at all because, OF COURSE, it is impossible evident!  
Thank you very much for stopping of intentional criminal Brigandage, wherein WIPO is also  
responsible for above demonstrative crime according to Art.1(1) and 51(1) PCT and Request. Sincerely  
yours Dr.Y.Zagzansky (e-mail: Kamel.Idris@wipo.int; became unworkable)

Supplements: Monstrous direct documents proving that European Governments are Brigands and  
are Unlawful & a Palermo (as only EXAMPLES).

a) Demonstrative criminal usurping falsification of EPO Unity Director. As one can see the level of  
Director of EPO Search Unity E. De Bandal intentionally falsified the signature (making its half- see  
below), moreover without sending of any juridically valid document since half of year). It is already  
irrevocably intentionally penal crime made by European Governments.

b) Falsification in forward LA PALERMO. EPO tries by anyway to stop my Application  
PCT/IB00/00463- EP038954.5 (with exemplary complete Search without any X and Y but with similar  
General scientific base construction). Wherein EPO's obstacle was in reality only crassable opposite  
sense of Rule 39(i) PCT. So, logically, they tried to falsify the illegal returning again to Examination.  
"So" in many years later de facto they wrote (Directorate General 21) that there is no Priority document  
(previously). It is difficult days for falsifiers of evident patent! (See separate page of signed by me papers  
it is evident, that the responsible intentional falsifiers of European Governments must be exemplary  
punished by at least "Disciplinary Board of Appeal", that could be later "Tribunal of Nuremberg" as Crime  
against Humanity with this very important Medicinal Applications. Earth must be burnt under foot of  
intentional very responsible falsifiers! *Y. Zagzansky*

(both pages are signed). Separate claim to miss. Good luck in the same envelope.

The procedure before the International Searching Authority (ISA) was closed by  
virtue of establishing and sending the International Search Report. There is no  
provision for review or appeal. Thus, the EPO can not grant my request to  
withdraw or amend the International Search Report.

As a final point, it should be mentioned that once you proceed into the  
regional phase before the EPO, a search may be carried out should the  
problems which led to the non-establishment of the Search Report in  
respect of certain claims be overcome (see "Guidelines for Examination in  
the EPO", B-VIII, 6.). Your arguments and proposed amendments of  
description and claims may then be taken into account.

Yours sincerely,

P. De Bandal  
E. De Bandal  
Director 1521

Fax: 41-22-740-14-35 VERY URGENT! For Dossier of Appl. PCT/EP02/02302 "End of AIDS for General Virology, based on profound science as protein folding: safe vaccines, universal antimicrobial means, mad cow end"

Dr. Y Zagjansky, Entraide, 22 rue Ste Marthe 75010 Paris  
General Director of World International  
Patent Organization, Geneva

WITHOUT DOUBT UNLEGAL, SA "SEARCH", MADE AS INTENTIONAL CRIMINAL SABOTAGE OF PCT CONVENTION, NOT ACCORDING TO PCT LAW, BUT FORMALLY OPENLY OPPOSITELY III: MUST BE CANCELED BY SUPERVISING: Art. 10, 51(1) WIPO: DISCIPLINARY PENALTY: CRIME OF INTENTIONAL SABOTAGE, IGNORING PCT CONVENTION! MUST BE DONE TOO.

Dear General Director! Demonstrating complete absence of law, Governmental EPO made "Search" Oppositely to written law for this Medicinal Application of century with end of AIDS, cancer, mad cow etc. Since June 03, with help of Mrs. M. Godbersen (IB), I received (03/09/03) finally letter without any (of counsel) concrete explanation of simple sabotage with intentionally falsified half of signature from Director 1521 EPO Search (see below) (who must be judged for this anyway). In spite of my clear evident answer I had no any answer neither from EPO, nor from WIPO during very long time. Only, justly in writing this letter, I received (26.05.04,) very strange letter of EPO Vice-Director, again without impossible explanation only because it is evidently impossible as anyone will surprise by simplicity of excess of arbitrary from below:

\$1- Simply oppositely! Ignored PCT Convention [cited by EPO, Rule 39(i) PCT], EPO does not search Claims 1, 2, 6 and 10 "as scientific theories" in knowing that this Rule obliges to make this Search according to PCT Guidelines (§9.05 in reference to this Rule!): "When viewing claims as a whole, if theories are applied or implemented to produce a practical application or to have technical character, search is required". Consequently, partial "Search" of sole claim 3, made without claims 1 and 2 is null and THIS SEARCH DOES NOT EXIST AT ALL!

\$2- Directly oppositely! Ignored law, EPO does not search claims 4, 5, 7-9, 11, 12 as generally for "large number of possible compounds" for use in therapy method. But directly according to law [cited in all these claims Art. 52(4)], in EPC (itself) (Art. 52), there are specially given references, obliging EPO to make search of the process of therapeutic method for being new and inventive with always given by me examples of substances for manufacture of such medicaments. It is too primitive sabotage in Medicine (AIDS, cancer, mad cow) based on processes "upon living things" ("PCT Guidelines" §5.12). Moreover, Search of above claims must be done with basic scientific theories (§1) as a whole (Rule 39(i) PCT).

\$3- And the above (§1, 2) was "the reason" of demonstrative sabotage of all Search and, of course (see also §5), of cynic absence of impossible explanations. But "problem" became urgent: I must enter in many National stages without Search (instead of best Search for XXI century preparations) due to only demonstrative sabotage to Search oppositely to PCT against initial PCT Request!

\$4. UP TO EPO: EPO is obliged to do this Urgent Search (a) with original text (even with better! claims!) or (b) with text certainly insignificantly modified (for EPO, too) or (c) with original and after this with little modified text: UP TO EPO: it is not TOO PRIMITIVE obstacle and EPO asked nothing else during "Search" (§1).

\$5. EPO responsible persons (Chief of Unity and Vice-President) wrote that "there is no provision for review or appeal" at International phase. It is too simple open misinformation. "EPO must, in carrying out international Search, be guided by the PCT Search Guidelines" (EPO Guidelines §8II-4.4, "Case Law of Boards of Appeal of EPO" §IX.C.1). And these Guidelines obliges EPO (§1.04): "Re-view of action of the Authority (ISA)" should take place when "such review is provided for under the applicable national law and practice". Wherein National EPO law stipulates: "Any decision of departments of the EPO are subject to review before a Board of Appeal" ("EPO Guidelines" General Introduction §3.2). Independently DE FACTO, it is ALSO directly confirmed by EPO Law ("Case Law", p.574): "There is no obstacle to making use of appeal procedures provided for under the EPC to supplement the provisions of the PCT" (with EPO as Designated Office too). Moreover, "all (according to EPO: EPO is 100% included!) PCT authorities in fact accept and duly consider any request for reconsideration!" ("Case Law", p.574) Y Zagjansky

But MOREOVER, the given EPO misinformation a priori CANNOT take place! With the same obvious §1, (both pages are signed) Y Zagjansky

2, at the same good text and THE SAME very good claims, EPO National phase must have good complete Search (as with any other good Application even with OBJECTIVE EPO errors) without additional payment. So by criminal intentional sabotage, I MUST lose International Search for all countries (without any my fault????), that will be good only at EPO National stage. It is impossible and incredible a priori, that is confirmed by above LAW!

But moreover, at intentional penal Totalitarian, ignoring PCT Convention (it means of Request!) and WIPO must immediately stop the ignoring of PCT Law (§1, 2), the Disciplinary Board of Appeal ("Law case" VIII-3.1.) punishes such penal crime too: "As such these provisions ("European Convention of Protection of Human Rights") should be considered part of the legal system of this Organization (EPO) and should be observed by all its departments" (wherein "penalty" must be "proportionate to the seriousness of the charges" - millions of euros and Crime against Humanity, justly).

SO THE "PROBLEM" IS ONLY IN §1 and 2, that are too obvious formally. And justly the EPO SPECIALISTS EXPRESSIVELY do not discuss it at all because, OF COURSE, it is impossibly evident! Thank you very much for stopping of intentional criminal Brigandage, wherein WIPO is also responsible for above demonstrative crime according to Art. 1(1) and 51(1) PCT and Request. Sincerely yours Dr. Y Zagjansky (e-mail Kamil.idris@wipo.int- became unworking).

Supplements: Monstrous direct documents proving that European Governments are Brigands and law Usurpers à la Palermo (as only EXAMPLES).

a) Demonstrative criminal usurping falsification of EPO Unity Director. As one can see the level of Director of EPO Search Unity E. De Bandel Intentionally falsified the signature (making its half- see below), moreover without sending of any juridically valid document since half of year). It is already irreversibly intentionally penal comme made by European Governments.

b) Falsification in forward à LA PALERMO. EPO tries by anyway to stop my Application PCT/IB00/00843- EP938954.5 (with exemplary complete Search without any X and Y but with similar General scientific base construction). Wherein EPO's obstacle was in reality only crashable opposite sense of Rule 39(i) PCT. So, logically, they tried to falsify the illegal returning again to Examination. "So" in many years later! de facto they wrote (Directorate General 2) that there is no Priority document neither in WIPO nor in EPO. It was a priori à la Palermo: there were 4 copies in 4!! Departments! (provent!). It is difficult days for falsifiers of evident patent! (See separate page of signed by me persons Y Zagjansky)

It is evident, that the responsible intentional falsifiers of European Governments must be exemplary punished by at least "Disciplinary Board of Appeal", that could be later "Tribunal of Nuremberg" as Crime against Humanity with this very important Medicinal Applications. Earth must be burnt under foots of intentional very responsible falsifiers!

(both pages are signed). Separate letter to Mrs. Godbersen in the same envelope Y Zagjansky

The procedure before the International Searching Authority (ISA) was closed by virtue of establishing and sending the International Search Report. There is no provision for review or appeal. Thus, the EPO can not grant your request to withdraw or amend the International Search Report.

As a final point, it should be mentioned that once you proceed into the regional phase before the EPO, a search may be carried out should the problems which led to the non-establishment of the Search Report in respect of certain claims be overcome (see "Guidelines for Examination in the EPO", B-VIII, 6.). Your arguments and proposed amendments of description and claims may then be taken into account.

Yours sincerely,

Y Zagjansky

E. De Bandel,  
Director 1521

for USPTO

18th August 2004

18 August 2004  
End Form T/IB/308 : 4942806  
beginning p. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000

Yuffe 18th Aug. 2004 3d sup.  
end p. 82 sup: "also "Guidelines"  
§C111-2.2.1 and"  
beginning Declaration about ONLY too!  
"Declaration about only to simple  
eliminations from dependent claims of"  
references for several previous claims".

**107505353**  
DT15 Rec'd PCT/PTO 24 AUG 2004

638,98,1991. 62. Ann.N.Y.Acad.Sci. 638,361,1991. 63. Oncogene 5,755,1999. 64. Protein Profile 2, 1173,1995. 65. Eur.J.Biochem. 232,425,1995. 66. Endocrine J. 2,249,1994. 67. EMBO J. 5,891,1986. 68. Proc.Natl.Acad.Sci.USA 82,7889,1995. 69. Breast Canc.Res.Treat. 40,231,1996. 70. Cancer Biochem.Biophys. 15,67,1995. 71. Curr.Opin.Cell.Biol. 5,48,1993. 72. Mol.Cel.Biol. 8,1775,1998. 73. J. Neurosci. 14,1130,1994. 74. J.Cell Biol. 126,1221,1994. 75. Differentiation 14,123,1979. 76. Biochem. J. 316,713,1996. 77. Biophys.J. 74,1914,1996. 78. Am.J.Physiol.-Cell Physiol. 39,C1532,1996. 79. Biol. Cell 84,139,1995. 80. Mol.Cell.Biol. 12,685,1992. 81. Nucl.Acid.Res. 23,2388,1995. 82. Mol.Cell.Biol. 13, 1572,1993. 83. Gen.Devel. 5,1464,1991. 84. Cell 61,255,1990. 85. Mol.Cell.Biol. 16,5444,1996. 86. Curr. Biol. 5,477,1993. 87. J.Med.Biol.Res. 29,895,1996. 88. Nucl.Acid.Res. 24,1753,1996. 89. EMBO J. 7, 3559,1988. 90. Nucl.Acid.Res. 23,4712,1995. 91. Mol.Cell.Biol. 9,5073,1989. 92. J.Cell.Biol. 115,887, 1991. 93. J.Biol.Chem. 266,19867,1991. 94. Mol.Cell.Biol.8,2737,1988; Publ. FR-98-06910. 95. Eur.J. Biochem. 63,166,1994. 96. Biochem.Soc.Transac. 24,521,1996. 97. Mol.Cell.Biol. 14,7984,1994. 98. J. Cell Biol. 126,1221,1994. 99. J.Neurosci. 16,1346,1996. 100. Gen.Compar.Endocrinol. 103,316,1996. 101. Nucl.Acid.Res. 24,4078,1996. 102. Eur.J.Neurosci. 7,2249, 1995. 103. Neuroscience 72,889,1996.

Part XI. 1.(Annex IA- Ref.1); Application Publication FR-2693656.

Annex IIIA. 1.(Annex IA- Ref.1); Application Publication FR-2693656. 2.Kandel ER et al "Principles of neural science" (Elsevier,1991); "The Heart and cardiovascular system" Ed. Fozzard HA et al (Raven Press,1991). 3. Adv.Exp.Med.Biol. 384,123,1995, 4. J.Neurophysiol. 78,3061,1997. 5. J.Neurophysiol. 78,3061,1997. 6. "Epilepsy. A Comprehensive test book", Ed. Engel J. & Pedby TA, 3 vol. (Lippincott-Raven, Phil, 1998). 7. Berne RM & Levy MN "Physiology" (CV Mosby Company, St. Louis, 1988). 8. Biophys. J. 68 (4 Suppl.),55S,1995.

Important supplement for Research- According to the Law.

According to the Law /for instance Art.52(3) of Convention of European Patent Office (EPO)- Administration charged for the International Search/: "The provisions of paragraph 2 (as patentability of discoveries and scientific theories AS SUCH) shall exclude patentability of the subject-matter or activities referred to in that provision only (ONLY) to the extent to which a European patent application.. relates to such... subject-matter or activities as such (it mean without their practical applications)". To see also Accords between EPO and World International Patent Organization "Gazette du PCT" 56/1997 (Appendix B): "are not excluded from research (PCT) or examination (PCT): all objects that are submitted to the research or examination according to national (European) procedure" Very clearly, as well in "Guidelines for Examination in European Patent Office"- §CIV-2.2.).

This direct stipulation is absolutely EQUIVALENT (since secondary school since 12 years old, since "their" Euclide) to the stipulation opposite to the inverse one: "If the European Patent Application concerns the subject-matters (as discoveries and scientific theories) with their applications (= "not as such"), they are patentable ONLY in this case"!

It stipulates clearly according to direct Law /stipulation opposite to the inverse one of Art.52.(3) (EPO)/, these subject-matters (like discoveries and scientific theories) are patentable only with their applications. Consequently, the claims, concerning "Theory or even principle underlining the invention" (letter T according to the Form of the EPO Research (to see also "Guidelines" §CIII-2.2.) and

Yaffez 1884 Aug. 04 2nd exp.  
end p. 87 (e 1) " § CIII-2.2. / and "  
beginning exp. 3 p. 87 " 638, 98, 1991. 62. Ann. N. Y."

638,98,1991. 62. Ann. N.Y. Acad. Sci. 638,361,1991. 63. Oncogene 5,755,1999. 64. Protein Profile 2, 1173,1995. 65. Eur. J. Biochem. 232,425,1995. 66. Endocrine J. 2,249,1994. 67. EMBO J. 5,891,1986. 68. Proc. Natl. Acad. Sci. USA 82,7889,1995. 69. Breast Canc. Res. Treat. 40,231,1996. 70. Cancer Biochem. Biophys. 15,67,1995. 71. Curr. Opin. Cell Biol. 5,48,1993. 72. Mol. Cell Biol. 8,1775,1998. 73. J. Neurosci. 14,1130,1994. 74. J. Cell Biol. 126,1221,1994. 75. Differentiation 14,123,1979. 76. Biochem. J. 316,713,1996. 77. Biophys. J. 74,1914,1996. 78. Am. J. Physiol.-Cell Physiol. 39,C1532,1996. 79. Biol. Cell 84,139,1995. 80. Mol. Cell Biol. 12,685,1992. 81. Nucl. Acid. Res. 23,2388,1995. 82. Mol. Cell Biol. 13, 1572,1993. 83. Gen. Devel. 5,1464,1991. 84. Cell 61,255,1990. 85. Mol. Cell Biol. 16,5444,1996. 86. Curr. Biol. 5,477,1993. 87. J. Med. Biol. Res. 29,895,1996. 88. Nucl. Acid. Res. 24,1753,1996. 89. EMBO J. 7, 3559,1988. 90. Nucl. Acid. Res. 23,4712,1995. 91. Mol. Cell Biol. 9,5073,1989. 92. J. Cell Biol. 115,887, 1991. 93. J. Biol. Chem. 266,19867,1991. 94. Mol. Cell Biol. 8,2737,1988; Publ. FR-98-06910. 95. Eur. J. Biochem. 63,166,1994. 96. Biochem. Soc. Transac. 24,521,1996. 97. Mol. Cell Biol. 14,7984,1994. 98. J. Cell Biol. 126,1221,1994. 99. J. Neurosci. 16,1346,1996. 100. Gen. Compar. Endocrinol. 103,316,1996. 101. Nucl. Acid. Res. 24,4078,1996. 102. Eur. J. Neurosci. 7,2249, 1995. 103. Neuroscience 72,889,1996.

Part XI. 1.(Annex IA- Ref.1); Application Publication FR-2693656.

Annex IIIA. 1.(Annex IA- Ref.1); Application Publication FR-2693656. 2. Kandel ER et al "Principles of neural science" (Elsevier,1991); "The Heart and cardiovascular system" Ed. Fozzard HA et al (Raven Press,1991). 3. Adv. Exp. Med. Biol. 384,123,1995, 4. J. Neurophysiol. 78,3061,1997. 5. J. Neurophysiol. 78,3061,1997. 6. "Epilepsy. A Comprehensive text book", Ed. Engel J. & Pedby TA, 3 vol. (Lippincott-Raven, Phil, 1998). 7. Berne RM & Levy MN "Physiology" (CV Mosby Company, St. Louis, 1988). 8. Biophys. J. 68 (4 Suppl.), 55S, 1995.

#### Important supplement for Research- According to the Law.

According to the Law /for instance Art.52(3) of Convention of European Patent Office (EPO)- Administration charged for the International Search/: "The provisions of paragraph 2 (as patentability of discoveries and scientific theories AS SUCH) shall exclude patentability of the subject-matter or activities referred to in that provision only (ONLY) to the extent to which a European patent application.. relates to such... subject-matter or activities as such (it mean without their practical applications)". To see also Accords between EPO and World International Patent Organization "Gazette du PCT" 56/1997 (Appendix B): "are not excluded from research (PCT) or examination (PCT): all objects that are submitted to the research or examination according to national (European) procedure" Very clearly, as well in "Guidelines for Examination in European Patent Office"- §CIV-2.2.).

This direct stipulation is absolutely EQUIVALENT (since secondary school since 12 years old, since "their" Euclide) to the stipulation opposite to the inverse one: "If the European Patent Application concerns the subject-matters (as discoveries and scientific theories) with their applications (= "not as such"), they are patentable ONLY in this case"!

It stipulates clearly according to direct Law /stipulation opposite to the inverse one of Art.52.(3) (EPO)/, these subject-matters (like discoveries and scientific theories) are patentable only with their applications. Consequently, the claims, concerning "Theory or even principle underlining the invention" (letter T according to the Form of the EPO Research (to see also "Guidelines" §CIII-2.2.) and

Yufinger 18th Aug. 2004 1st exp.  
End p. 82 exp. 1: " Int. 2. Pharmaceut. 134,  
193, 1996. Ex 5 "  
(1st exp) beginning p. 87: " 638, 98, 1991, 62. Ann. "

638,98,1991. 62. Ann. N.Y. Acad. Sci. 638,361,1991. 63. Oncogene 5,755,1999. 64. Protein Profile 2, 1173,1995. 65. Eur. J. Biochem. 232,425,1995. 66. Endocrine J. 2,249,1994. 67. EMBO J. 5,891,1986. 68. Proc. Natl. Acad. Sci. USA 82,7889,1995. 69. Breast Canc. Res. Treat. 40,231,1996. 70. Cancer Biochem. Biophys. 15,67,1995. 71. Curr. Opin. Cell. Biol. 5,48,1993. 72. Mol. Cell. Biol. 8,1775,1998. 73. J. Neurosci. 14,1130,1994. 74. J. Cell Biol. 126,1221,1994. 75. Differentiation 14,123,1979. 76. Biochem. J. 316,713,1996. 77. Biophys. J. 74,1914,1996. 78. Am. J. Physiol.-Cell Physiol. 39,C1532,1996. 79. Biol. Cell 84,139,1995. 80. Mol. Cell. Biol. 12,685,1992. 81. Nucl. Acid. Res. 23,2388,1995. 82. Mol. Cell. Biol. 13, 1572,1993. 83. Gen. Devel. 5,1464,1991. 84. Cell 61,255,1990. 85. Mol. Cell. Biol. 16,5444,1996. 86. Curr. Biol. 5,477,1993. 87. J. Med. Biol. Res. 29,895,1996. 88. Nucl. Acid. Res. 24,1753,1996. 89. EMBO J. 7, 3559,1988. 90. Nucl. Acid. Res. 23,4712,1995. 91. Mol. Cell. Biol. 9,5073,1989. 92. J. Cell. Biol. 115,887, 1991. 93. J. Biol. Chem. 266,19867,1991. 94. Mol. Cell. Biol. 8,2737,1988; Publ. FR-98-06910. 95. Eur. J. Biochem. 63,166,1994. 96. Biochem. Soc. Transac. 24,521,1996. 97. Mol. Cell. Biol. 14,7984,1994. 98. J. Cell Biol. 126,1221,1994. 99. J. Neurosci. 16,1346,1996. 100. Gen. Compar. Endocrinol. 103,316,1996. 101. Nucl. Acid. Res. 24,4078,1996. 102. Eur. J. Neurosci. 7,2249, 1995. 103. Neuroscience 72,889,1996.

Part XI. 1.(Annex IA- Ref.1); Application Publication FR-2693656.

Annex IIIA. 1.(Annex IA- Ref.1); Application Publication FR-2693656. 2. Kandel ER et al "Principles of neural science" (Elsevier,1991); "The Heart and cardiovascular system" Ed. Fozzard HA et al (Raven Press,1991). 3. Adv. Exp. Med. Biol. 384,123,1995, 4. J. Neurophysiol. 78,3061,1997. 5. J. Neurophysiol. 78,3061,1997. 6. "Epilepsy. A Comprehensive test book", Ed. Engel J. & Pedby TA, 3 vol. (Lippincott-Raven, Phil,1998). 7. Berne RM & Levy MN "Physiology" (CV Mosby Company, St. Louis, 1988). 8. Biophys. J. 68 (4 Suppl.),55S,1995.

Important supplement for Research- According to the Law.

According to the Law /for instance Art.52(3) of Convention of European Patent Office (EPO)- Administration charged for the International Search/: "The provisions of paragraph 2 (as patentability of discoveries and scientific theories AS SUCH) shall exclude patentability of the subject-matter or activities referred to in that provision only (ONLY) to the extent to which a European patent application.. relates to such... subject-matter or activities as such (it mean without their practical applications)". To see also Accords between EPO and World International Patent Organization "Gazette du PCT" 56/1997 (Appendix B): "are not excluded from research (PCT) or examination (PCT): all objects that are submitted to the research or examination according to national (European) procedure" Very clearly, as well in "Guidelines for Examination in European Patent Office"- §CIV-2.2.).

This direct stipulation is absolutely EQUIVALENT (since secondary school since 12 years old, since "their" Euclide) to the stipulation opposite to the inverse one: "If the European Patent Application concerns the subject-matters (as discoveries and scientific theories) with their applications (= "not as such"), they are patentable ONLY in this case"!

It stipulates clearly according to direct Law /stipulation opposite to the inverse one of Art.52.(3) (EPO)/, these subject-matters (like discoveries and scientific theories) are patentable only with their applications. Consequently, the claims, concerning "Theory or even principle underlining the invention" (letter T according to the Form of the EPO Research (to see also "Guidelines" §CIII-2.2.) and



Yupik 18th Aug. 2004 3d exp.  
end exp. p. 82 :,, 134, 193, 1996. 13. EXS"  
beginning p. 87 (1st exp) :,, 638, 98, 1991. "

- 3,965,1990. 26.Immunol.Today 13,301,1992. 27.Microbiol.Rev. 57,183,1993. 28.AIDS 3,475,1989. 29.Curr.Opin.Immunol. 2,414,1990. 30.Microbiol.Rev. 57,183,1993. 31.Ann.N.Y.Acad.Sci. 727,50,1994. 32.Virology 186,261,1992. 33.Nature 337,368,1989. 34.Proc.Natl.Acad.Sci.USA 86,4287,1989. 35.AIDS 10(Suppl.A),S33,1996.
- 5 36.J.Acquir.Immune Defic.Syindr. 3,319,1990. 37.J.Med.Primatol. 22,154,1993. 38.Immunol.Lett. 51,107,1996. 39.AIDS 10,689,1996. 40.J.Trop.Pediatr.42,116,1996. 41.Science 268,1612,1995. 42.Annu.Rev.Med. 41,331,1990. 43.Clin.Microbiol.Rev. 10,86,1997. 44.J.Infect.Dis. 158,124,1988. 45.Transplant.Proc. 20,Suppl.1,661,1988. 46.Semin.Pediatr.Surg. 2,218,1993. 47.Nippon Rinsho 54,1529,1996. 48.Oncogene
- 10 13,427,1996. 49.Annu.Rev.Immunol. 12, 593,1994. 50.Immunol.Cell.Biol. 74,513,1996. 51.Virology 225,111,1996. 52.J.Infect.Dis. 174,1098,1996. 53.Immunology 82,410,1994. 54.J.Infect.Dis.Suppl. 99,30,1995. 55.Scand.J.Infect.Dis.Suppl. 99,34,1995. 56.Transplantation 61,1757,1996. 57.J.Virol. 71,1521,1997. 58.Scand.J.Infect.Dis.Suppl. 99,43,1995. 59.Virology 197,143,1993. 60.Cell 76,301,1994. 61."Fields Virology"
- 15 Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2221. 62.J.Virol. 67,2209,1993. 63."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2343. 64.J.Virol. 67,2918,1993. 65. J.Infect.Dis. 165,994,1992. 66."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia, 1996), p.2231. 67."Fields Virology"
- 20 Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia), p.2297. 68.Virology 224,214,1996. 69.Virology 179,487,1990. 70.J.Interferon Res. 14,319,1994. 71.Pharmacol.Ther. 65,415,1995. 72.AIDS Res.Hum.Retroviruses 12,1273,1996. 73.Virology 221,1,1996. 74.J.Gen.Virol. 75,1211,1994. 75.Annu.Rev.Cell Biol. 8,365,1992. 76.J.Virol. 68,2830,1994. 77.Am.J.Pathol. 134,223,1989. 78.Adv.Neuroimmunol. 5,327,1995.
- 25 79.Clin.Infect.Dis. 19,500,1994. 80.Vet.Microbiol. 55,277,1997. 81.Proc.Natl.Acad.Sci.USA 91,1932,1994. 82.Microb.Pathog. 14,275,1993. 83.N.Engl.J.Med. 322,1648,1990. 84.Nature 362,103,1993. 85.Int.Arch.Allergy Immunol. 103,128,1994. 86.Zagyansky Y. International Patent Publication N°WO 99/56288 (04/11/99) and WO 00/52989 (14.09.00.) "Einstein- Bohr End: New Atomic Scale Physics, Electric field: neutrinos and electrons in conversions, perpetual
- 30 motion, development: seisms, extinguished volcan, created islands, Big Bang Energy" - full text in <http://pctgazette.wipo.int> 87.Infect.Control.Hosp.Epidemiol. 17,532,1996.
- Part VI. 1."Immunochemistry-Labfax" Eds. Kerr MA & Thorpe R. (Biosci. Publishers, Oxford, 1994). 2.Harlow E. & Lane D. "Anticorps. Un Manuel de Laboratoire" (Prodel, Paris, 1991). 3."Methods in Molecular Biology": vol.51 "Antibody engineering protocols". 4.J.Am.Chem.Soc. 116, 6508,1994. 5.Scand.J.Immunol. 49,311,1999. 6.Meth.Enzymol. 70,156,1980. 7.Anal.Biochem. 156, 220,1986. 8.FEBS Lett. 231,281,1988. 9.Rehm HJ & Reed G. "Biotechnology", 12 vol.,( Wiley-VCH, 1988). 10.Scriban R."Biotechnologie", (Technique & Documentation, Paris, 1999).
- 35 Part VII. 1.Proc.Natl.Acad.Sci. 95,13233,1998. 2.J.Gen.Virol. 77,1837,1996. 3.Science 229,1402, 1985. 4.Science 228,593,1985. 5.Eur.J.Biochem. 260,482,1999. 6.J.Neurosci.Res. 33,639,1992. 7.Bio- essays 12,173 and 223,1990. 8.J.Biol.Chem. 268,4922,1993. 9.Exp.Eye Res. 47,53,1988. 10.Biochim. Biophys.Acta 986,106,1989. 11.Protein Sci. 3,1953,1994. 12.Int.J.Pharmaceut. 134,193,1996. 13.EXS
- 40

Yusuf 18th August 2004 2nd exp.  
end of 1st p. 82: 13. EXS  
beginning 3rd exp. p. 82: 3, 965, 1990. 26. Immune.  
Today 13, 301, 1992. 27. Literature. Rev. 57, ..."

- 3,965,1990. 26.Immunol.Today 13,301,1992. 27.Microbiol.Rev. 57,183,1993. 28.AIDS 3,475,1989. 29.Curr.Opin.Immunol. 2,414,1990. 30.Microbiol.Rev. 57,183,1993. 31.Ann.N.Y.Acad.Sci. 727,50,1994. 32.Virology 186,261,1992. 33.Nature 337,368,1989. 34.Proc.Natl.Acad.Sci.USA 86,4287,1989. 35.AIDS 10(Suppl.A),S33,1996.
- 5 36.J.Acquir.Immune Defic.Syndr. 3,319,1990. 37.J.Med.Primatol. 22,154,1993. 38.Immunol.Lett. 51,107,1996. 39.AIDS 10,689,1996. 40.J.Trop.Pediatr.42,116,1996. 41.Science 268,1612,1995. 42.Annu.Rev.Med. 41,331,1990. 43.Clin.Microbiol.Rev. 10,86,1997. 44.J.Infect.Dis. 158,124,1988. 45.Transplant.Proc. 20,Suppl.1,661,1988. 46.Semin.Pediatr.Surg. 2,218,1993. 47.Nippon Rinsho 54,1529,1996. 48.Oncogene 10,427,1996. 49.Annu.Rev.Immunol. 12, 593,1994. 50.Immunol.Cell.Biol. 74,513,1996.
- 10 51.Virology 225,111,1996. 52.J.Infect.Dis. 174,1098,1996. 53.Immunology 82,410,1994. 54.J.Infect.Dis.Suppl. 99,30,1995. 55.Scand.J.Infect.Dis.Suppl. 99,34,1995. 56.Transplantation 61,1757,1996. 57.J.Virol. 71,1521,1997. 58.Scand.J.Infect.Dis.Suppl. 99,43,1995. 59.Virology 197,143,1993. 60.Cell 76,301,1994. 61."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2221. 62.J.Virol. 67,2209,1993. 63."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2343. 64.J.Virol. 67,2918,1993. 65.J.Infect.Dis. 165,994,1992. 66."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia, 1996), p.2231. 67."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia), p.2297. 68.Virology 224,214,1996. 69.Virology 179,487,1990. 70.J.Interferon Res. 14,319,1994. 71.Pharmacol.Ther. 65,415,1995. 72.AIDS Res.Hum.Retroviruses 12,1273,1996. 73.Virology 221,1,1996. 74.J.Gen.Virol. 75,1211,1994. 75.Annu.Rev.Cell Biol. 8,365,1992. 76.J.Virol. 68,2830,1994. 77.Am.J.Pathol. 134,223,1989. 78.Adv.Neuroimmunol. 5,327,1995.
- 25 79.Clin.Infect.Dis. 19,500,1994. 80.Vet.Microbiol. 55,277,1997. 81.Proc.Natl.Acad.Sci.USA 91,1932,1994. 82.Microb.Pathog. 14,275,1993. 83.N.Engl.J.Med. 322,1648,1990. 84.Nature 362,103,1993. 85.Int.Arch.Allergy Immunol. 103,128,1994. 86.Zagyansky Y. International Patent Publication N°WO 99/56288 (04/11/99) and WO 00/52989 (14.09.00.) "Einstein- Bohr End: New Atomic Scale Physics, Electric field: neutrinos and electrons in conversions, perpetual motion, development: seisms, extinguished volcans, created islands, Big Bang Energy" - full text in <http://pctgazette.wipo.int> 87.Infect.Control.Hosp.Epidemiol. 17,532,1996.
- 30 Part VI. 1."Immunochemistry-Labfax" Eds. Kerr MA & Thorpe R. (Biosci. Publishers, Oxford, 1994). 2.Harlow E. & Lane D. "Anticorps. Un Manuel de Laboratoire" (Prodel, Paris, 1991). 3."Methods in Molecular Biology": vol.51 "Antibody engineering protocols". 4.J.Am.Chem.Soc. 116, 6508,1994. 5.Scand.J.Immunol. 49,311,1999. 6.Meth.Enzymol. 70,156,1980. 7.Anal.Biochem. 156, 220,1986. 8.FEBS Lett. 231,281,1988. 9.Rehm HJ & Reed G. "Biotechnology", 12 vol.,( Wiley-VCH, 1988). 10.Scriban R."Biotechnologie", (Technique & Documentation, Paris, 1999).
- 35 Part VII. 1.Proc.Natl.Acad.Sci. 95,13233,1998. 2.J.Gen.Virol. 77,1837,1996. 3.Science 229,1402, 1985. 4.Science 228,593,1985. 5.Eur.J.Biochem. 260,482,1999. 6.J.Neurosci.Res. 33,639,1992. 7.Bio- essays 12,173 and 223,1990. 8.J.Biol.Chem. 268,4922,1993. 9.Exp.Eye Res. 47,53,1988. 10.Biochim. Biophys.Acta 986,106,1989. 11.Protein Sci. 3,1953,1994. 12.Int.J.Pharmaceut. 134,193,1996. 13.EXS
- 40

Yef Boger 18 Aug. 04 1ST exp.

end of "Dele" what optional corrects":  
" 2720506, 2720622 + New Emerald Street "  
beginning of 2nd exp p. 82: " 3, 965, 1980, 26 Immanuel.  
Friday 13, ... "

- 3,965,1990. 26.Immunol.Today 13,301,1992. 27.Microbiol.Rev. 57,183,1993. 28.AIDS 3,475,1989. 29.Curr.Opin.Immunol. 2,414,1990. 30.Microbiol.Rev. 57,183,1993. 31.Ann.N.Y.Acad.Sci. 727,50,1994. 32.Virology 186,261,1992. 33.Nature 337,368,1989. 34.Proc.Natl.Acad.Sci.USA 86,4287,1989. 35.AIDS 10(Suppl.A),S33,1996.
- 5 36.J.Acquir.Immune Defic.Syndr. 3,319,1990. 37.J.Med.Primatol. 22,154,1993. 38.Immunol.Lett. 51,107,1996. 39.AIDS 10,689,1996. 40.J.Trop.Pediatr.42,116,1996. 41.Science 268,1612,1995. 42.Annu.Rev.Med. 41,331,1990. 43.Clin.Microbiol.Rev. 10,86,1997. 44.J.Infect.Dis. 158,124,1988. 45.Transplant.Proc. 20,Suppl.1,661,1988. 46.Semin.Pediatr.Surg. 2,218,1993. 47.Nippon Rinsho 54,1529,1996. 48.Oncogene 10,427,1996. 49.Annu.Rev.Immunol. 12, 593,1994. 50.Immunol.Cell.Biol. 74,513,1996. 51.Virology 225,111,1996. 52.J.Infect.Dis. 174,1098,1996. 53.Immunology 82,410,1994. 54.J.Infect.Dis.Suppl. 99,30,1995. 55.Scand.J.Infect.Dis.Suppl. 99,34,1995. 56.Transplantation 61,1757,1996. 57.J.Virol. 71,1521,1997. 58.Scand.J.Infect.Dis.Suppl. 99,43,1995. 59.Virology 197,143,1993. 60.Cell 76,301,1994. 61."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2221. 62.J.Virol. 67,2209,1993. 63."Fields Virology" Eds.Fields BN, Knipe DM & Howley PM (Lippincott-Raven Publishers, Philadelphia, 1996),p.2343. 64.J.Virol. 67,2918,1993. 65. J.Infect.Dis. 165,994,1992. 66."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia, 1996), p.2231. 67."Fields Virology" Eds.Fields BN et al (Lippincott-Raven Publishers, Philadelphia), p.2297. 68.Virology 224,214,1996. 69.Virology 179,487,1990. 70.J.Interferon Res. 14,319,1994. 71.Pharmacol.Ther. 65,415,1995. 72.AIDS Res.Hum.Retroviruses 12,1273,1996. 73.Virology 221,1,1996. 74.J.Gen.Virol. 75,1211,1994. 75.Annu.Rev.Cell Biol. 8,365,1992. 76.J.Virol. 68,2830,1994. 77.Am.J.Pathol. 134,223,1989. 78.Adv.Neuroimmunol. 5,327,1995.
- 20 79.Clin.Infect.Dis. 19,500,1994. 80.Vet.Microbiol. 55,277,1997. 81.Proc.Natl.Acad.Sci.USA 91,1932,1994. 82.Microb.Pathog. 14,275,1993. 83.N.Engl.J.Med. 322,1648,1990. 84.Nature 362,103,1993. 85.Int.Arch.Allergy Immunol. 103,128,1994. 86.Zagyansky Y. International Patent Publication N°WO 99/56288 (04/11/99) and WO 00/52989 (14.09.00.) "Einstein- Bohr End: New Atomic Scale Physics, Electric field: neutrinos and electrons in conversions, perpetual motion, development: seisms, extinguished volcan, created islands, Big Bang Energy" - full text in <http://pctgazette.wipo.int> 87.Infect.Control.Hosp.Epidemiol. 17,532,1996.
- 30 Part VI. 1."Immunochemistry-Labfax" Eds. Kerr MA & Thorpe R. (Biosci. Publishers, Oxford, 1994). 2.Harlow E. & Lane D. "Anticorps. Un Manuel de Laboratoire" (Prodel, Paris, 1991). 3."Methods in Molecular Biology": vol.51 "Antibody engineering protocols". 4.J.Am.Chem.Soc. 116, 6508,1994. 5.Scand.J.Immunol. 49,311,1999. 6.Meth.Enzymol. 70,156,1980. 7.Anal.Biochem. 156, 220,1986. 8.FEBS Lett. 231,281,1988. 9.Rehm HJ & Reed G. "Biotechnology", 12 vol.,( Wiley-VCH, 1988). 10.Scriban R."Biotechnologie", (Technique & Documentation, Paris, 1999).
- 35 Part VII. 1.Proc.Natl.Acad.Sci. 95,13233,1998. 2.J.Gen.Virol. 77,1837,1996. 3.Science 229,1402, 1985. 4.Science 228,593,1985. 5.Eur.J.Biochem. 260,482,1999. 6.J.Neurosci.Res. 33,639,1992. 7.Bio- essays 12,173 and 223,1990. 8.J.Biol.Chem. 268,4922,1993. 9.Exp.Eye Res. 47,53,1988. 10.Biochim. Biophys.Acta 986,106,1989. 11.Protein Sci. 3,1953,1994. 12.Int.J.Pharmaceut. 134,193,1996. 13.EXS
- 40

**DECLARATION ABOUT OPTIONAL CORRECTION OF SLIPS IN pages 82 and 87.**

I, Zagjansky Yuly, sole inventor of Application PCT/EP02/02302, make the following optional corrections of slips. Slips. p.82 (lines 35-37): missed (but cited) references in Part. VI (N°N°5-10). p.87 (lines 15-21): missed (but cited) References of Chapters XI and Annex IIIA. p.87 (22-39): exactly retyped "Important supplement for Search" without mention of AT Office (it was impossible alternative for ISA). [Below, see page 52 with accepted by IPEA numerous new references in Specification for my Application PCT/IB00/00843]. Paris, 11th August 2004. All pages are signed by me verso with date of 08/11/04.

*Yuly Zagjansky* 18th August 2004

IB0000843

- 52 -

one of Art.52(3) these subject-matters (like discoveries and scientific theories) are patentable only with their applications (!). Consequently, the claims, concerning "Theory or (EVEN!) principle underlying the invention" (letter "T" according the Form of the EPO Research) (to see also "Guidelines.." §CIII-2.2.) and claims, concerning their practical consequences must be considered ONLY ENSEMBLE, according to the law. Consequently, I present here the (priliminary) International Classification of Patents with the mentions of the corresponding claim Groups, serving to the establishment of each I.C.P. element.

Claims 1,2,3,5: H02K 44/00; G01P 3/50; G01B 11/03; G01R 5/00, 33/00; G01T 5/00; G01J 3/00. Claims 3,4,6: G01T 1/00; G01J 3/00; G21H 7/00; G21K 1/00, 7/00; G02B 23/00; G01B 15/00; G21G 1/00, 5/00. Claims 3,4,7: G01T 1/00, 7/00, 7/02, 7/04, 7/06, 3/00; G21G 1/00, 5/00; H05H 6/00; G21C 23/00; G21K 5/08; G21D 5/00; G01T 7/02. Claims 3,4,8: G21K 1/00; H02N 1/00; H02K 44/00; G01V 7/00. Claims 3,4,9: G01P 3/50; G01B 11/03; G02B 23/00; H01H 35/02; B65G; B65G 47/22. Claims 3,4,10: G01R 5/00, 33/00; G01J 3/00; G01T; G01W 1/00; G01V 3/00. Claims 3,4,11: G01R 5/00, 33/00; G01J 3/00; G01T; G01W; G01V 1/00, 3/00, 1/104, 1/157; E02B 17/00; E02F. Claims 3,4,12: G21K 1/00, 5/08, 7/00; H02N 1/00.

Unity of Invention (S-03 /1998, "Gazette du PCT"). I develop here the New Atomic Scale (Microworld) Physics (instead of the "Einstein-Bohr" Physics of XX century, established by Greatest geniuses) with this "sole general" conception with absolutely (and often opposite) new principal bases and revolutionary (for milliards of years) concrete applications. Evidently such new field (even the new Science!) general invention entitles the new general claims /".. an invention which open up a whole field is entitled to more generally in the claims than one which is concerned with advances in a known technology" ("Guidelines.." - §CIII-2.2.)). But I guarantee the Unity of Invention also (also) with the help of the discovered New Force in the Atom, conducting futher to the net negation of all basic foundations of the Einstein-Bohr Physics, constructed from beginning of XX century and to the creation of the Absolutely New Atomic scale Physics, with the titanic applications in the sure continuous chain of the sure inventive discoveries, "considered as one whole, relatively to the technical field" where the developed continuous components of these chains (claims) "contain all characteristics of the previous ones" ("Gazette du PCT" S-03/1998 p.46). So the Unity of Invention is made in the double form.

MANY BEST PATENTS OF COMMON MEANS, FITTING TO GIVEN CODES, EASILY TAKEN FROM CD-ROM.

(p.48): a. H01H 35/02, B95G 47/00, B65G 47/22: WO 00/21052, 89/10623, 84/04962, 00/01921, 01/27006; EP:707193, 595446, 813214, 480131, 463291, 253790, 124269, 706028, 305940, 125839, 502248, 124269; FR 2560115, 2519947, 2490197. b. c. G01V (3/00, 1/00), G01W 1/00: WO 01/77712, 00/13647, 01/38903, 00/77755, 00/51093, 95/25966, 01/77702, 01/79873, 99/13358, 98/53345, 98/19750 91/19210; EP 1120629, 718639, 829736, 422895; FR 2779530, 2542453, 2424542, 2670532. G01V 1/104, 1/157, E02F, E02B 17/00: WO 00/63724, 97/48967, 92/11546, 90/13830, 01/79614, EP 1136648, 518427, 1147265. d. G21K 1/00, H02N 1/00, H02K 44/00: WO 00/14750, 00/14759, EP 1112578, 235896. (p.18): G01T 7/02, /04, /06: WO 00/69769, 00/25152; EP 234150, 404681, 008967; FR 2770648, 2729765, 2720506, 2619622.

AMENDED SHEET

Yuliy Pavlov 18th August 04  
end of a [redacted] to Form PTO-1380 cheque:  
"2. Form PCT/138/308. [redacted] 11 August 2004  
with attached to this Form cheque N° 020720  
for \$460/day from staples) (1 January 2004)  
regarding of temp. pay 82: "3,965, 1990. 26. Im-  
munology. Today..."

**10/505534**

DT15 Rec'd PCT/PTO 2.4 AUG 2004



CODE: SOCIÉTÉ GÉNÉRALE  
AGENCE GROUPE PARIS SEINE AMONT  
LOGISTIQUE UNIFIÉE  
31/35 Rue Froideveaux  
(FRANCE) 75014 PARIS  
S.G. 03085

SOCIÉTÉ GÉNÉRALE  
A FRENCH BANK FOUNDED IN 1864

08072

PARIS 10/08/2004 1-2  
210

SOCIÉTÉ GÉNÉRALE 460.00 USD

DOLLARS-U.S.\$

460, /

TO  
THE  
ORDER  
OF

PAYABLE AT

COMMISSIONER OF PATENTS AND TRADE MARKS  
OF USPTO

JPMORGAN CHASE BANK  
NEW YORK, NY 10017

P. 1216 Ed. 04.2003

⑈080720⑈ ⑆021000021⑆0011714359⑈

SOCIÉTÉ GÉNÉRALE  
AGENCE... S.G. 03085  
(FRANCE)

DETACH AND RETAIN THIS VOUCHER  
THE ATTACHED CHECK IS IN PAYMENT OF ITEMS DESCRIBED BELOW.  
IF NOT CORRECT PLEASE NOTIFY US PROMPTLY. NO RECEIPT DESIRED.

DATE	DESCRIPTION	AMOUNT
10/08/2004	VIRE. D ORDRE M <sup>me</sup> ZAGYANSKY.	USD 460,

DELUXE BUSINESS FORMS 1-800-328-0304

VBG097.CDR

Items 11 to 20 below concern document(s) or information included:

- 11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
- 12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
- 13. ☒ A preliminary amendment.
- 14. ☐ An Application Data Sheet under 37 CFR 1.76.
- 15. ☐ A substitute specification.
- 16. ☐ A power of attorney and/or change of address letter.
- 17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
- 18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
- 19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
- 20. ☒ Other items or information: 1.Covering letter with cheque for \$460 and letter Supplements; 2.Form PCT/IB/308.

page 1 of 2

Yuf...  
18th August 2004

Yuf... 11 August 2004

with attached to this Form (1 January 2004)  
cheque N° 080720 for \$460 (by four staples)

Yuliy 18th August 2004  
end of PTO/SB/09: "Commissioner for Patents,  
Washington, DC 20231 "  
beginning of Declaration about optional cor-  
rection of slips: "I, Zaynarsky Yuliy, sole inven-  
tor of Application PCT/EP02/02302, make ..."

Yuliyagin 18th August 2004  
end of envelope Clearance!  
" on 0825 801 801 \*0,98FTTC (0,148) G  
minute an 01/0.  
01/10/2000" Yuliyagin  
beginning of page four PTO-1350, Form PTO-1350  
(REV. 10-2000) U.S. DEPARTMENT OF...

**IMPORTANT!** AT SENDING OF MONEY AT POST, AT  
CHECKING, I HAD PUT THE CITY "ALEXANDRIA" IN  
**ALL** THREE COPIES OF "MANDAT INTERNATIONAL"  
WITH MY SPECIAL BLACK SIGNATURE PEN, AS HERE

Yuliyagin 18 August 2004  
18th August 2004

**VERSO**

**LA POSTE**

**FICHE DE DÉPÔT D'UN ENVOI INTERNATIONAL**

**- RECOMMANDÉ**  
**- AVEC VALEUR DÉCLARÉE**

A remplir par l'expéditeur

Destinataire : Mail Stop PCT, Commissioner for Patents, US Patent and Trademark Office,  
P.O. Box 1450, Alexandria 22313-1450

Localité Alexandria

Pays Virginia, USA

Réservé au service

75100 PARIS LOUVRE RP

étiquette 510	date N°	AR	PR Prix	*H	vd	Nature	signature de l'agent
	16/08/04	12.50EUR		ES			
	08665	81.99FRF					
		0206g		Poids		crbt	

517/517 bis

VOIR AU DOS

RCS Nanterre B 356 000 000



# MANDAT INTERNATIONAL

PAYS DE DESTINATION **USA**

☐ EXPRESS ☒ AUTRE - non urgent

Ecrivez en majuscules, lisez bien les précisions figurant au verso ⇨

## MONTANT

Montant à transférer 460,000 Devise USD (Dollar USA)

Montant en chiffres

quatre cent soixante dollars US

Montant en lettres

## EXPEDITEUR

☐ Madame ☐ Mademoiselle ☒ Monsieur

ZAGYANSKY

Nom de l'expéditeur (ou raison sociale de l'entreprise)

YULY

Prénoms

Adresse (pour remboursement du mandat en France en cas de non paiement)

CONTRAI DE, 22 RUE STE MARTE

75010 PARIS

Code postal Ville

Numéro de téléphone (pour vous joindre en cas de problème)

**BENEFICIAIRE** ☐ Madame ☐ Mademoiselle ☒ Monsieur

COMMISSIONER FOR PATENTS

Nom du bénéficiaire (ou raison sociale de l'entreprise)

Prénoms

☒ PAIEMENT EN ESPECES

Adresse du bénéficiaire

UNITED STATES PATENT AND TRADEMARK

OFFICE, P.O. BOX 1450, ALEXANDRIA

22313 VIRGINIA, USA

Code postal Région ou état

☐ VERSEMENT SUR UN COMPTE POSTAL (non admis en express) : Centre de chèques :

Compte du bénéficiaire

**MESSAGE A TRANSMETTRE AU BENEFICIAIRE** (admis selon les pays, se renseigner au guichet)

APPL. PCT/EP 02/02302, BASIC FEE,

APPLICANT ZAGYANSKY

**OPTION EXPRESS** : Notification au bénéficiaire par ☒ Fax ☐ Téléphone ☐ E-mail (voir au verso)

FAX : 17038729306

PAYS : AMERIQUE (ETATS-UNIS)

Bureau	Date	Numéro	Catégorie	Montant transféré	Montant déposé	Service
756250	16/08/04	0023	ESPE	*****460.00 USD	386,55 EUR	2535.60 FRF
					Frais	
					17,30 EUR	113.48 FRF
					Taxe	
					0,00 EUR	0.00 FRF
					1 EUR = 6.559570 FRF	
				TOTAL PERCU	403,85 EUR	2649.08 FRF

1 EUR = 1.190000 USD

BUREAU : PARIS ODEON


Cadre réservé aux opérations manuelles

Bureau	Date	Numéro	Catégorie	Montant transféré	Montant déposé en euros
--------	------	--------	-----------	-------------------	-------------------------

Frais

TOTAL PERCU

RCS PARIS 356 000 000




RECEPISSE A REMETTRE AU CLIENT

18th August 04

**VERSO**





XD 104 666 931 FR

Pour toute information sur votre envoi appelez le Service Clients au 0825 801 801\* ou consultez le minitel 3615 ou 3617 Chronopost\*\* ou Internet : www.chronopost.com

Votre n° d'envoi est le :

XD 104 666 931 FR Clé: 10 48

EXPEDITEUR : Emballage et transport payés. Enveloppe 1. Résistance maximum 250 G

Nom DOCTOR Y. ZAGYANSKY  
Adresse ENTRAIDE, 22 RUE STE MARTE

Code postal 75010 Ville PARIS  
Pays FRANCE  
Personne à contacter Exemple: M. Dupont

DESTINATAIRE Exemple: Expéditeur

Nom COMMISSIONER FOR PATENTS  
Adresse P.O. BOX 1450, ALEXANDRIA, VIRGINIA

Code postal 22313-1450 Ville ALEXANDRIA  
Etat/Province VIRGINIA

Pays USA  
Personne à contacter 1-703-305-3257

CONTENU DE L'ENVOI : NOM ET SIGNATURE DE L'EXPÉDITEUR  
DATE  
TIMBRE A

Information on Contracting States

UNITED STATES OF AMERICA

General information

Name of Office: United States Patent and Trademark Office (USPTO)

Location: 220 30th Street, S.W., Crystal Plaza 2, Arlington, Virginia 22202, United States of America

Mailing address: Mail Stop PCT, Commissioner for Patents, P.O. Box 13, Alexandria, Virginia 22313-1600, USA

Telephone: (1-703) 305 3230

Facsimile machine: (1-703) 305 32 30

Telex: TWX 710 955 0671 Arlington, Virginia, USA

Internet: <http://www.uspto.gov/pat>

RESTRICTIONS A LA PRISE EN CHARGE

D'une manière générale et sans que cette liste soit limitative, ne peuvent être pris en charge :  
- toutes marchandises relevant des réglementations nationales et internationales sur les produits dangereux tels que notamment définis par les règlements IATA comme, de façon non exhaustive, les munitions, les gaz, les matières inflammables, radioactives, toxiques ou corrosives, ainsi que tous les objets qui, par leur nature ou leur conditionnement, peuvent présenter un danger pour l'environnement, la sécurité des engins de transport, ou endommager les autres colis transportés.  
- les bijoux, pierres et métaux précieux, les monnaies, devises, billets de banque, valeurs financières, les titres de paiement (cartes de crédit, chèques, effets de commerce, titres au porteur...), les animaux vivants ou morts, les marchandises sous température dirigée, les armes à feu, les stupéfiants, les objets d'art, les publications ou supports audiovisuels interdits par toute loi ou réglementation applicable, ainsi que les réponses à appels d'offres pour lesquelles CHRONOPOST propose un service spécifique.  
A l'international, outre les objets relevant des restrictions ci-dessus, ne peuvent être pris en charge :  
- les journaux, alcools non alimentaires, plantes et dérivés périssables, valeurs négociables en bourse et tous les objets non admis à l'importation dans le pays de destination.

CONSEILS IMPORTANTS

- ❶ Pour des raisons douanières, les catégories d'objets suivantes ne sont pas admises dans cette enveloppe : bandes magnétiques, billets d' avion, brochures, catalogues, disquettes, livres, matériel publicitaire, partitions, papeterie, passeports, plans, photographies commerciales, tissu.
- ❷ Dans certains pays, les journaux, magazines et livres, font également l'objet de restrictions.
- ❸ Complétez lisiblement au stylo à bille noir et en lettres majuscules le document de transport. N'oubliez pas d'inscrire le nom de la personne à contacter et son numéro de téléphone pour nous permettre de la joindre en cas de besoin.
- ❹ Inscrivez l'adresse géographique (numéro et nom de la voie) de votre destinataire :

PAYS DESSERVIS

Canada  
Etats-Unis d'Amérique  
(y compris Alaska, Hawaï  
et Porto Rico)  
Mexique

Pour vérifier  
une destination :

[www.chronopost.com](http://www.chronopost.com)  
ou 0825 801 801

\*0,98F TTC (0,14€) la minute  
au 01/10/2000\*

*Yuliy Zagayansky*  
*18th Aug 2004*  
*Exp USPTO*

Appl. PCT/EP02/02302. Paris, 16th August 04

(Fax: 1-703-872-9306)

Mail Stop PCT, COMMISSIONER for PATENTS, USPTO, P.O. Box 1450, Alexandria, VA, USA. PCT/EP02/02302

Dear Sir, 11th August 04, I sent the "Chronopost" to this USPTO Official "Mailing address", that was communicated as "delivered" by Internet (see www.chronopost.org, N°XD104666931FR and here) in 2 hours after arrival in New York airport. Very fortunately, I could certainly determine: it is (without doubt) false delivery in New York area but not in D.C. (north of VA) area in 350 km!! to south. In view of thousands and thousands of such letters arriving in USPTO with this address (with postal code of VA close to D.C.) without any problem and moreover with even!! printed geographic location (copy of PCT Applicant's Guide) pasted (it is only at my envelope and with blue colour) on the envelope too (see copy of envelope with telephone too), it looks again like organized crime (Brigandage) of STATE-like post to lie, until end of limit entry date! So instead of special cheque (N°08072) made in dollars (\$460), that was in envelope (attached by 4 staples to Form PTO-1390), I had to send again these money by post (see receipt) and separately (this time) to send "simple" registered letter from Central Post (Paris-Louvre N° ). This is also text of post letter wherein after this, I assure (as before) presence of all pages, in writing on each page end of previous page and beginning of next page with date and my signature (with cercle) (in order as in Supplement of Covering letter of 08/11/04 with Supplement, copy of Chronopost envelope, Internet track, Receipt of postal sending of \$460 as firstly in cercle). Evidently there is no cheque in this 2nd letter.

Limited Supplements in Fax: 1. Covering letter of 08/11/04. 2. Copy of Chronopost Envelope (= OPEN BRIGANDAGE of 100% of experienced). 3. Copy of Internet Track with 100% false delivery in N.Y.??? 4. (for basic fee) Receipt of sending of \$460. 5. Copy of Receipt of Registered letter. 6. Form PTO-1390. 7. Declaration about optional correction of slips (pp.82, 87). 8. Corrected pp.82 and 87. 9. Copy of my letter to Director of WIPO (first 2 pages, 05/28/04). 10. Copy of cheque, stapled to PTO-1390 (sent in Chronopost).

COVERING LETTER.

*Yuliy Zagyansky* 18th August 2004

Application N°PCT/EP02/02302, filing date 04th March 2002, title: "End of AIDS for general Virology based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end"

Commissioner of Patents

Dr.Y.Zagyansky, Entraide, 22 rue Ste Marthe, 75010

USPTO

75010 Paris France

Paris, 11th August 2004

Dear Sir, I am entering into National US phase of my above PCT application

(see form PTO- 1390 here). §1. Original English text of this Application was transmitted by International Bureau to you, according to your demand (Art.20) (see form PCT/IB/308) and I am entering with this original text. Only optionally, I corrected obvious slips at typing some references (it is only in Supplement of Specification in List of References that were numbered and described already in Specification). Even giving of MANY new references IN SPECIFICATION was accepted without any problem by EPO-IPEA (see copy here) at my another application (PCT/IB00/00843) according to direct law ("EPO Guidelines" §CII-4.3.). (And it was justly accepted at EPO National entry of this Application).

§2. Because, the US law forbids reference (in dependent claims) for two previous claims connected with "and", I very simply and naturally eliminate one of references in such claims. I did it for International phase only for easier orientation although it was not necessary.

§3. The International Search of this application is done by 100% illegal way and was not corrected neither by EPO (ISA) nor by with help of Director of WIPO. It is too evident demonstrative intentional GROTESQUE. See here my letter of 05/28/04 and 06/17/04 to Director of WIPO (fixed with stamp of French Office in my letter of 06/22/04 to its Director) and also, separately, the copy of this letter of 05/28/04- 2 first pages.

§4. I am original sole independent inventor of this Application with small unity status, who does not have any agreement concerning this application.

!!!§5. In view of very special "strange" course of my Applications, I must ask here very important question about "Notice of Abandonment". In US law, concerning "Certificat of mailing or transmission" (37 CRF §1.8, §512 MPEP) there is no mention about, even declaration, FOR nonreceiving of USPTO letters (ONLY of USPTO letters!), but only text about Certificat of mailing or transmission of Applicant letter. Does it mean that USPTO finally send the registered letter wherein USPTO is sure about their receiving by Applicant and such Declaration (for nonreceiving of USPTO letter) is not needed consequently? Thank you very much for forward explanation of this TOO important information. The heavy common truth is coming from Governmental Office? Thank you very much (only due to Internet making USPTO men) for very net comings!

Sincerely yours Dr.Y.Zagyansky. Supplements: 1. Forms PTO-1390, PTO/SB/01, PTO/SB/09. 2. Copy of Cheque for \$460 for basic fee, attached to Form PTO-1390 with staples. 3. Declaration about optional replacement (100% slips moreover with Supplement of reference List) of pp.82 and 87 with new pp.82 and 87 in 3 copies (with replaced with IPEA p.52 of PCT/IB00/00843). 4. Declaration about too simple eliminations from dependent claims of reference for several previous claims with pp.92, 93, 96-98 (concerning claims 3-5, 7-9, 11). 5. Form PCT/IB/308. 6. My letter to Director of French Office (with its stamp of 22 June 04) with my letter to Director of WIPO of 28th May 04 and 17th June 04. 7. My letter to Director of WIPO of 28th May 2004 (2 first pages). 8. Abstract of this Application (3 copies). All replaced pages of all copies are signed (verso) by me (as well all Forms at all pages) with date of 11th August 2004. In the case of receiving of both sums, each of \$460, to communicate immediately by e-mail: zagyansky5.yuly@laposte.net. Immediately, I shall enter my Appl. PCT/IB03/03315 for US Natl.phase with help of this resting sum. 9. FORM PTO-2038 in two PARALLEL VARIANTS. *Yuliy Zagyansky* 18 Aug. 2004

VERSO

Yuf Yuffagne 18th August 2004

beginning of page d'envelope of  
champort : "XD 104 666 931 FR  
pour suite l'information sur vote .."  
end of Form PTO-2038 Vap. 2 : "correct one  
accuracy do §1)." "

Important. At sending of money at Post, at  
checking, I had put the city "ALEXANDRIA" in  
THREE COPIES OF "MANDAT INTERNATIONAL"  
WITH MY SPECIAL BLACK SIGNATURE PEN, AS HERE

Yuffagne

VER 50



DECLARATION ABOUT ONLY too simple eliminations from dependent claims of references for several previous claims.

I, Zagyansky Yuly, sole Inventor of Application PCT/EP02/02302, make the following too simple elimination of unneeded references for numerous precedent claims (generally making simple photocopies of published pages).

p.92-40 (line 40) (for claim 3): claim (instead of: claims).

p.93-1 (for claim 3): 1 [instead of: 1(8, 10, 14) and 2].

p.93 (lines 8,9) (for claim 5): claim 1 [instead of: claims 1 (1-5, 8)].

p.96 (lines 7,8) (for claim 7): claim 6 [instead of: claims 1(16), 2 and 6].

p.97-7 (for claim 8): claim 7 [instead of: claims 1, 2, 6 and 8] (also too obvious slip: 7 instead of 8).

p.97 (lines 27, 28) (for claim 9): claim 6 [instead of: claims 1, 2 and 6 (19,20)].

p.98-20 (for claim 11): claim 6 (instead of: claims 1 and 6).

Paris, 11th August 2004. All pages are signed by me verso with date of 08/11/04.

Yuly Zagyansky 18th August 2004

W. J. Ray 18/12 Aug. 2004 (1st exp.) one exp.  
end p. 87 3 exp: "Research (to see also "Guarantees"  
§ C(II) - 2.2.) and "  
beginning p. 92 (1st exp) : "recognition cell"

10/505534

DT15 Rec'd PCT/PTO 24 AUG 2004

receptor cell machinery (of chimpanzee) and the HIV prevent (logically) the 2nd contamination and the AIDS phase (chimpanzee "immunity")

(12) The baby macrophages are more active than that of adult and the baby immune system can already product the antibodies very quickly after the birth, but the 2nd AIDS phase can take place only since ~3 months of age due to the created carbohydrate pattern correspondence between the baby macrophage Fc receptor machinery and HIV virus and, generally, the 2nd contamination can take place due to the very weak transmitted dozes.

(13) The 1st macrophage contamination is made by the macrophage- tropic clones as well the 2nd contamination with also T-cell contaminations, and the T cell- tropic clones provoke the creation of syncytia that undergo the regulated and accelerated apoptosis and the phagocytosis (by macrophages) by the relatively small, almost unvisible, quantities.

(14) Principally, the vaccination must aggravate the contamination due to the antibodies, that help to the contamination, but due to the vaccination with the homogenous envelope proteins, the strong productive contamination is more problematic and these homogenous antibodies can make some decrease of the viral particle quantity (precipitation) and also some blocking of the 1st entry although in the case of the powerful 2nd HIV entry (with CD4 receptor help) there are the dangerous spontaneous re-enterings.

(15) The restricted HIV-2 contaminations take place because of a weaker variability of the viral proteins during the 1st contamination and a stronger differences between the host and virus carbohydrate patterns.

(16) The discrete switching signal due to the specific interactions between the CD4 molecules and the viral envelope proteins, important for AIDS development, are determined by a more general biological molecular processes.

Claim 2. The principal characteristics of the AIDS development process /(a): there is the 1st productive contamination with the cell motility utilisation; (b) the infection increase depends on the antibodies; (c) there is the protein heterogeneity during the 1st contamination, necessary for the heterogenous antibody production, obligatory for 2nd contamination/ according Claim 1 characterized in that a number of other viral Families possesses them.

Claim 3. The viral exterior proteins (envelope or capsule) /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ /for manufacture of medicaments pour vaccinations against viruses (like influenza A-influenza/pneumonia)/ with one (anyway with minimal possible quantity) viral neutralizing epitope and/or one (minimally possible) viral homogenous clone that must be taken for the immunization characterized in that the increase of the virus contaminations is minimal (zero) because the corresponding anti-viral antibodies could increase the cell contaminations with the Fc receptor help wherein the heterogeneity of these antibodies is, generally, obligatory for the virus entry according Claim

Letter 18th August 04 1st exp.  
and "Declaration about [redacted] to Simple" with date of  
08/11/04. Letter 18th August 2004".  
beginning of p 92 (2nd exp) : "reception cell machinery"

receptor cell machinery (of chimpanzee) and the HIV prevent (logically) the 2nd contamination and the AIDS phase (chimpanzee "immunity")

(12) The baby macrophages are more active than that of adult and the baby immune system can already product the antibodies very quickly after the birth, but the 2nd AIDS phase can take place only since ~3 months of age due to the created carbohydrate pattern correspondence between the baby macrophage Fc receptor machinery and HIV virus and, generally, the 2nd contamination can take place due to the very weak transmitted dozes.

(13) The 1st macrophage contamination is made by the macrophage- tropic clones as well the 2nd contamination with also T-cell contaminations, and the T cell- tropic clones provoke the creation of syncytia that undergo the regulated and accelerated apoptosis and the phagocytosis (by macrophages) by the relatively small, almost invisible, quantities.

(14) Principally, the vaccination must aggravate the contamination due to the antibodies, that help to the contamination, but due to the vaccination with the homogenous envelope proteins, the strong productive contamination is more problematic and these homogenous antibodies can make some decrease of the viral particle quantity (precipitation) and also some blocking of the 1st entry although in the case of the powerful 2nd HIV entry (with CD4 receptor help) there are the dangerous spontaneous re-enterings.

(15) The restricted HIV-2 contaminations take place because of a weaker variability of the viral proteins during the 1st contamination and a stronger differences between the host and virus carbohydrate patterns.

(16) The discrete switching signal due to the specific interactions between the CD4 molecules and the viral envelope proteins, important for AIDS development, are determined by a more general biological molecular processes.

Claim 2. The principal characteristics of the AIDS development process /(a): there is the 1st productive contamination with the cell motility utilisation; (b) the infection increase depends on the antibodies; (c) there is the protein heterogeneity during the 1st contamination, necessary for the heterogenous antibody production, obligatory for 2nd contamination/ according Claim 1 characterized in that a number of other viral Families possesses them.

Claim 3. The viral exterior proteins (envelope or capsule) /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ /for manufacture of medicaments pour vaccinations against viruses (like influenza A-influenza/pneumonia)/ with one (anyway with minimal possible quantity) viral neutralizing epitope and/or one (minimally possible) viral homogenous clone that must be taken for the immunization characterized in that the increase of the virus contaminations is minimal (zero) because the corresponding anti-viral antibodies could increase the cell contaminations with the Fc receptor help wherein the heterogeneity of these antibodies is, generally, obligatory for the virus entry according Claim

Yefreys 18th August 2004 (1) 2nd exp 2nd exp.  
and p 92 1st exp: "according claims" the Dep.  
before p 92 3d exp: "reception all machinery of"

receptor cell machinery (of chimpanzee) and the HIV prevent (logically) the 2nd contamination and the AIDS phase (chimpanzee "immunity")

(12) The baby macrophages are more active than that of adult and the baby immune system can already product the antibodies very quickly after the birth, but the 2nd AIDS phase can take place only since ~3 months of age due to the created carbohydrate pattern correspondence between the baby macrophage Fc receptor machinery and HIV virus and, generally, the 2nd contamination can take place due to the very weak transmitted dozes.

(13) The 1st macrophage contamination is made by the macrophage- tropic clones as well the 2nd contamination with also T-cell contaminations, and the T cell- tropic clones provoke the creation of syncytia that undergo the regulated and accelerated apoptosis and the phagocytosis (by macrophages) by the relatively small, almost invisible, quantities.

(14) Principally, the vaccination must aggravate the contamination due to the antibodies, that help to the contamination, but due to the vaccination with the homogenous envelope proteins, the strong productive contamination is more problematic and these homogenous antibodies can make some decrease of the viral particle quantity (precipitation) and also some blocking of the 1st entry although in the case of the powerful 2nd HIV entry (with CD4 receptor help) there are the dangerous spontaneous re-enterings.

(15) The restricted HIV-2 contaminations take place because of a weaker variability of the viral proteins during the 1st contamination and a stronger differences between the host and virus carbohydrate patterns.

(16) The discrete switching signal due to the specific interactions between the CD4 molecules and the viral envelope proteins, important for AIDS development, are determined by a more general biological molecular processes.

Claim 2. The principal characteristics of the AIDS development process /(a): there is the 1st productive contamination with the cell motility utilisation; (b) the infection increase depends on the antibodies; (c) there is the protein heterogeneity during the 1st contamination, necessary for the heterogenous antibody production, obligatory for 2nd contamination/ according Claim 1 characterized in that a number of other viral Families possesses them.

Claim 3. The viral exterior proteins (envelope or capsule) /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ /for manufacture of medicaments pour vaccinations against viruses (like influenza A-influenza/pneumonia)/ with one (anyway with minimal possible quantity) viral neutralizing epitope and/or one (minimally possible) viral homogenous clone that must be taken for the immunization characterized in that the increase of the virus contaminations is minimal (zero) because the corresponding anti-viral antibodies could increase the cell contaminations with the Fc receptor help wherein the heterogeneity of these antibodies is, generally, obligatory for the virus entry according Claim.

Yuffen 18th August 2004 3rd rep.  
end p. 2nd rep.: "entry according claim"  
beginning: "1 claim". The substances "



1

Claim 4. The substances /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ (for manufacture of medicaments against encephalites), that stop the macrophage motility (as antibodies against the  $\beta$ -chemokine receptors), characterized in that this motility is obligatory for the contaminated macrophage entering into brain to cause the encephalites (as those of CMV origin) according Claim 1

Claim 5. The kit of preparations for the determination of the real titers of the different viruses, with the action, similar to the two HIV phases, according Claims 1

/and Art.52(4) EPO and Art.2(2) AT- law of 1970/ characterized in that for the 1st phase determination: one creates the concentration gradients of the chemokines (as  $\beta$ -chemokines) to switch the macrophage mobility to approach to the conditions of the 1st contamination in vivo, and for the 2nd phase contamination: one utilizes the heterogenous anti-env antibodies (similar to those in vivo) to approach to the conditions of the 2nd contamination in vivo.

Claim 6. The real characteristics of the signalling events that follow the process of the signal switching, produced by the interaction between gp120 and CD4 molecules of the "general process of AIDS development by HIV lentiviruses" of claim 1, are established from the general fundamental processes of the protein foldings and recognitions in the cells, characterized by following characteristics:

(1) There are the chaperon specializations for each glycosylation type: N-, O- and GAG-, that determine the Universal specialities of a limited chaperon number for a protein enormous number by their carbohydrate chains, specialized due to the law of the homologous intercarbohydrate interactions.

(2) There are the two principal pathways of the protein foldings: endoplasmic reticulum→Golgi and in cytoplasm.

(3) The calnexin (chaperon of ER) is monoglycosylated and it is attached to the N-monoglycosylated proteins after the elimination of two other glucoses.

(4) The calnexin makes the complexes with the calreticulin (ER) due to their homologous O-carbohydrates of their similar structures wherein it is the calreticulin that is responsible for the complex with the BiP and grp 94 chaperons later.

(5) During the 1st "trip" in Golgi (ER→Golgi→ER→Golgi), (a) the proteolysis of the terminal N-end (or C- one) (creation of the peptide, named , Du-2T- like) must take place due to the convertases in Golgi; (b) the gag glycosylation must (can) take place.

(6) The creation of the definitive complex, moreover in ER, of the gp96/grp94 chaperon ("boat") with the BiP, calreticulin, p50-like proteins (GAG specificity), peptidyl-prolyl isomerase (PPI) and protein-disulfide isomerase (PDI) (principally) must take place.

(7) The cytoplasmic folding of the polypeptides, yet attached to the ribosomes in cytoplasm, takes place.

Yuf. Bogdanov 18th August 2004 1st exp  
end p.92 3d exp. "In the virus entry according claim"  
beginning p.93 2nd exp: "1 claim 4. The substances /Bst. "

1

Claim 4. The substances /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ (for manufacture of medicaments against encephalites), that stop the macrophage motility (as antibodies against the  $\beta$ -chemokine receptors), characterized in that this motility is obligatory for the contaminated macrophage entering into brain to cause the encephalites (as those of CMV origin) according Claim 1

Claim 5. The kit of preparations for the determination of the real titers of the different viruses, with the action, similar to the two HIV phases, according Claims 1

/and Art.52(4) EPO and Art.2(2) AT- law of 1970/ characterized in that for the 1st phase determination: one creates the concentration gradients of the chemokines (as  $\beta$ -chemokines) to switch the macrophage mobility to approach to the conditions of the 1st contamination in vivo, and for the 2nd phase contamination: one utilizes the heterogenous anti-env antibodies (similar to those in vivo) to approach to the conditions of the 2nd contamination in vivo.

Claim 6. The real characteristics of the signalling events that follow the process of the signal switching, produced by the interaction between gp120 and CD4 molecules of the "general process of AIDS development by HIV lentiviruses" of claim 1, are established from the general fundamental processes of the protein foldings and recognitions in the cells, characterized by following characteristics:

(1) There are the chaperon specializations for each glycosylation type: N-, O- and GAG-, that determine the Universal specialities of a limited chaperon number for a protein enormous number by their carbohydrate chains, specialized due to the law of the homologous intercarbohydrate interactions.

(2) There are the two principal pathways of the protein foldings: endoplasmic reticulum→Golgi and in cytoplasm.

(3) The calnexin (chaperon of ER) is monoglycosylated and it is attached to the N-monoglycosylated proteins after the elimination of two other glucoses.

(4) The calnexin makes the complexes with the calreticulin (ER) due to their homologous O-carbohydrates of their similar structures wherein it is the calreticulin that is responsible for the complex with the BiP and grp 94 chaperons later.

(5) During the 1st "trip" in Golgi (ER→Golgi→ER→Golgi), (a) the proteolysis of the terminal N-end (or C- one) (creation of the peptide, named , Du-2T- like) must take place due to the convertases in Golgi; (b) the gag glycosylation must (can) take place.

(6) The creation of the definitive complex, moreover in ER, of the gp96/grp94 chaperon ("boat") with the BiP, calreticulin, p50-like proteins (GAG specificity), peptidyl-prolyl isomerase (PPI) and protein-disulfide isomerase (PDI) (principally) must take place.

(7) The cytoplasmic folding of the polypeptides, yet attached to the ribosomes in cytoplasm, takes place.

Yi He 17th August 2004 2nd exp.

end p.93 1st exp'n taken place, "

beginning p.93 3d exp'n 1 claim 4. The substances  
/ Art. 52 (4) "

1

Claim 4. The substances /Art.52(4) EPO, Art.2(2) AT (law of 1970)/ (for manufacture of medicaments against encephalites), that stop the macrophage motility (as antibodies against the  $\beta$ -chemokine receptors), characterized in that this motility is obligatory for the contaminated macrophage entering into brain to cause the encephalites (as those of CMV origin) according Claim 1

Claim 5. The kit of preparations for the determination of the real titers of the different viruses, with the action, similar to the two HIV phases, according Claims 1

/and Art.52(4) EPO and Art.2(2) AT- law of 1970/ characterized in that for the 1st phase determination: one creates the concentration gradients of the chemokines (as  $\beta$ -chemokines) to switch the macrophage mobility to approach to the conditions of the 1st contamination in vivo, and for the 2nd phase contamination: one utilizes the heterogenous anti-env antibodies (similar to those in vivo) to approach to the conditions of the 2nd contamination in vivo.

Claim 6. The real characteristics of the signalling events that follow the process of the signal switching, produced by the interaction between gp120 and CD4 molecules of the "general process of AIDS development by HIV lentiviruses" of claim 1, are established from the general fundamental processes of the protein foldings and recognitions in the cells, characterized by following characteristics:

(1) There are the chaperon specializations for each glycosylation type: N-, O- and GAG-, that determine the Universal specialities of a limited chaperon number for a protein enormous number by their carbohydrate chains, specialized due to the law of the homologous intercarbohydrate interactions.

(2) There are the two principal pathways of the protein foldings: endoplasmic reticulum→Golgi and in cytoplasm.

(3) The calnexin (chaperon of ER) is monoglycosylated and it is attached to the N-monoglycosylated proteins after the elimination of two other glucoses.

(4). The calnexin makes the complexes with the calreticulin (ER) due to their homologous O-carbohydrates of their similar structures wherein it is the calreticulin that is responsible for the complex with the BiP and grp 94 chaperons later.

(5) During the 1st "trip" in Golgi (ER→Golgi→ER→Golgi), (a) the proteolysis of the terminal N-end (or C- one) (creation of the peptide, named , Du-2T- like) must take place due to the convertases in Golgi; (b) the gag glycosylation must (can) take place.

(6) The creation of the definitive complex, moreover in ER, of the gp96/grp94 chaperon ("boat") with the BiP, calreticulin, p50-like proteins (GAG specificity), peptidyl-prolyl isomerase (PPI) and protein-disulfide isomerase (PDI) (principally) must take place.

(7) The cytoplasmic folding of the polypeptides, yet attached to the ribosomes in cytoplasm, takes place.

Yu Page 18th August 2004 3rd exp.  
end p. 2nd exp: "cytoplasm, takes place."  
beginning p. 96 1st exp: "hydrogen homologous."  
Evidences between C.D. 4"

hydrogen homologous liaisons between CD4 and gp120 chains already, that is "abated" definitively by the dissociation of the corresponding "Du-2T"-like proteins wherein as a result of the strong conformational change, the other intramolecular liaisons are broken, leading to the agglomerate creations with the membrane melting due to the intercarbohydrate dehydration.

Claim 7. The little proteins (peptides) Du-2T like ("Du-2T") of the synthesized, by ER→Golgi, proteins, including all membranous receptors (as CD4 or gp120) of claim 6 characterized in that they are obtained from N- or C- proprotein ends after the limited proteolysis, they are hidden at the protein surface by the 2 carbohydrate chains with the homologous intercarbohydrate interactions, they are situated near the site of the 2 prolines and S-S bond(s) (source of the irreversible folding with tension) and its dissociation changes the state of the general structure of these proteins profoundly and discretely in liberating the carbohydrate chains for the intermolecular interactions (for formation of the complex aggregate as in the case of the membranous receptors or/and activation of other molecules) like these real little proteins (peptides) for IgG (and also for Fc receptors and receptors for antigen), characterized in that they are situated in the CH2 region and they dissociate after the hapten (antigen) interaction with the active sites because of the consecutive dissociation of the intramolecular coupled interactions of the covering homologous chains in liberating these immunoglobulin chains from already intermolecular interactions: with N-carbohydrate chains of the complement (C1q) (in activating it) or with the carbohydrates of other receptors: Fc and for antigen and with other carbohydrate chains of plasma membrane (PM); like the little real proteins (peptides) (although exceptionally special) Du-2T- like for the molecules MHC class I, characterized in that they are found in "the active site", created by the  $\alpha 1$  and  $\alpha 2$  domains of the MHC  $\alpha$ -chain with the several prolines of these subdomains wherein "the dissociation" of this peptide (Du-2T -like) in the active site of the TRC provokes the strong change of the general structure of the MHC-I  $\alpha$  chain, where the sole N-chain carbohydrate (without pair at invariable site) of this subunit can already interact with the corresponding carbohydrate chain (of the invariable site) of the TCR  $\alpha$ -chain (also without pair) to switch the "Du-2T" dissociation from the MHC  $\alpha 3$  domain with the 2 covering carbohydrate chains, the dissociation, from TCR, of its "Du-2T" (also there is the presence of the prolines, S-S and two symmetric N-carbohydrate chains) (very exceptional presence of the charged amino acids in the intramembranous domains of all components of TCR facilitates the conformational changes due to instability) and the mutual intermolecular interactions of the O- and N- chains of MHC with those of TCR and the CD8 molecules (having own "Du-2T") and between the carbohydrate chains of the same PM (during the complete signal); and like the functional GPI-anchored proteins (so called priones), synthesized by ER→Golgi (in complex aggregate of the classical complete signal) that make the self-aggregation in pathology (diseases

Yef 18th August 1st exp:

end p. 93 3d exp: "in cytochrome, takes place"  
beginning p. 96 (2nd) 2nd exp: "hydrogen homologous  
transfers between".



hydrogen homologous liaisons between CD4 and gp120 chains already, that is "abated" definitively by the dissociation of the corresponding "Du-2T"-like proteins wherein as a result of the strong conformational change, the other intramolecular liaisons are broken, leading to the agglomerate creations with the membrane melting due to the intercarbohydrate dehydration.

Claim 7. The little proteins (peptides) Du-2T like ("Du-2T") of the synthesized, by ER→Golgi, proteins, including all membranous receptors (as CD4 or gp120) of claim 6 characterized in that they are obtained from N- or C- proprotein ends after the limited proteolysis, they are hidden at the protein surface by the 2 carbohydrate chains with the homologous intercarbohydrate interactions, they are situated near the site of the 2 prolines and S-S bond(s) (source of the irreversible folding with tension) and its dissociation changes the state of the general structure of these proteins profoundly and discretely in liberating the carbohydrate chains for the intermolecular interactions (for formation of the complex aggregate as in the case of the membranous receptors or/and activation of other molecules) like these real little proteins (peptides) for IgG (and also for Fc receptors and receptors for antigen), characterized in that they are situated in the CH2 region and they dissociate after the hapten (antigen) interaction with the active sites because of the consecutive dissociation of the intramolecular coupled interactions of the covering homologous chains in liberating these immunoglobulin chains from already intermolecular interactions: with N-carbohydrate chains of the complement (C1q) (in activating it) or with the carbohydrates of other receptors: Fc and for antigen and with other carbohydrate chains of plasma membrane (PM); like the little real proteins (peptides) (although exceptionally special) Du-2T- like for the molecules MHC class I, characterized in that they are found in "the active site", created by the  $\alpha 1$  and  $\alpha 2$  domains of the MHC  $\alpha$ -chain with the several prolines of these subdomains wherein "the dissociation" of this peptide (Du-2T -like) in the active site of the TRC provokes the strong change of the general structure of the MHC-I  $\alpha$  chain, where the sole N-chain carbohydrate (without pair at invariable site) of this subunit can already interact with the corresponding carbohydrate chain (of the invariable site) of the TCR  $\alpha$ -chain (also without pair) to switch the "Du-2T" dissociation from the MHC  $\alpha 3$  domain with the 2 covering carbohydrate chains, the dissociation, from TCR, of its "Du-2T" (also there is the presence of the prolines, S-S and two symmetric N-carbohydrate chains) (very exceptional presence of the charged amino acids in the intramembranous domains of all components of TCR facilitates the conformational changes due to instability) and the mutual intermolecular interactions of the O- and N- chains of MHC with those of TCR and the CD8 molecules (having own "Du-2T") and between the carbohydrate chains of the same PM (during the complete signal); and like the functional GPI-anchored proteins (so called priones), synthesized by ER→Golgi (in complex aggregate of the classical complete signal) that make the self-aggregation in pathology (diseases

Yefrag 18 Aug 04 2nd exp.  
(end p 98 1st exp) Yefrag  
end p. 96 1st exp: " (discusses "  
beginning p. 96 3d exp: " hydrogen homologues  
relationships between CD4 and "

hydrogen homologous liaisons between CD4 and gp120 chains already, that is "abated" definitively by the dissociation of the corresponding "Du-2T"-like proteins wherein as a result of the strong conformational change, the other intramolecular liaisons are broken, leading to the agglomerate creations with the membrane melting due to the intercarbohydrate dehydration.

Claim 7. The little proteins (peptides) Du-2T like ("Du-2T") of the synthesized, by ER→Golgi, proteins, including all membranous receptors (as CD4 or gp120) of claim 6 characterized in that they are obtained from N- or C- proprotein ends after the limited proteolysis, they are hidden at the protein surface by the 2 carbohydrate chains with the homologous intercarbohydrate interactions, they are situated near the site of the 2 prolines and S-S bond(s) (source of the irreversible folding with tension) and its dissociation changes the state of the general structure of these proteins profoundly and discretely in liberating the carbohydrate chains for the intermolecular interactions (for formation of the complex aggregate as in the case of the membranous receptors or/and activation of other molecules) like these real little proteins (peptides) for IgG (and also for Fc receptors and receptors for antigen), characterized in that they are situated in the CH2 region and they dissociate after the hapten (antigen) interaction with the active sites because of the consecutive dissociation of the intramolecular coupled interactions of the covering homologous chains in liberating these immunoglobulin chains from already intermolecular interactions: with N-carbohydrate chains of the complement (C1q) (in activating it) or with the carbohydrates of other receptors: Fc and for antigen and with other carbohydrate chains of plasma membrane (PM); like the little real proteins (peptides) (although exceptionally special) Du-2T- like for the molecules MHC class I, characterized in that they are found in "the active site", created by the  $\alpha 1$  and  $\alpha 2$  domains of the MHC  $\alpha$ -chain with the several prolines of these subdomains wherein "the dissociation" of this peptide (Du-2T -like) in the active site of the TRC provokes the strong change of the general structure of the MHC-I  $\alpha$  chain, where the sole N-chain carbohydrate (without pair at invariable site) of this subunit can already interact with the corresponding carbohydrate chain (of the invariable site) of the TCR  $\alpha$ -chain (also without pair) to switch the "Du-2T" dissociation from the MHC  $\alpha 3$  domain with the 2 covering carbohydrate chains, the dissociation, from TCR, of its "Du-2T" (also there is the presence of the prolines, S-S and two symmetric N-carbohydrate chains) (very exceptional presence of the charged amino acids in the intramembranous domains of all components of TCR facilitates the conformational changes due to instability) and the mutual intermolecular interactions of the O- and N- chains of MHC with those of TCR and the CD8 molecules (having own "Du-2T") and between the carbohydrate chains of the same PM (during the complete signal); and like the functional GPI-anchored proteins (so called priones), synthesized by ER→Golgi (in complex aggregate of the classical complete signal) that make the self-aggregation in pathology (diseases

Yufeng 18 Aug. 2004 3 exp.

end p. 96 exp: in pathology  
1 disease " beginning p. 97 1st exp:  
" as lead "

as Mad Cow or Jacob-Creutzfeldt) (this time, without signal already, but like during the signal!), due to the interactions with the forms of these proteins where the "Du-2T" is dissociated already and the carbohydrate chains (hiding) are free for already homologous intermolecular aggregation, facilitating already the dissociation (facilitated also generally!) the dissociation of the "Du-2T" of other molecules.

Claim 8. The large number of the different little proteins (peptides) (Du-2T-like = "Du-2T") according Claim 7 for the manufacture of the medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ against (1) the undesirable process of the complement activation; (2) the cell lysis; (3) the action of the particular membranous receptors; (4) the action of the parasites as the viruses and also bacteria, protozoans, mashrooms; (5) the creation of the dangerous priones (so called aggregated "scarpie" form) during the diseases as Mad Cow or Creutzfeldt-Jacob; (6) the protein aggregation in solutions (in blood included) characterized in that the simple introduction of these "Du-2T" proteins must stop the corresponding undesirable processes in preventing the dissociation of their native analogues where such dissociation would provoke the harmful signalling including the pathological diseases /(1)-(5)/ or the intermolecular glycoprotein aggregation in solution (6).

Claim 9. The well charged affine molecules (as antibodies) against the distinct HIV surface molecules (or those of other viruses and other parasites like bacteria or mashrooms or against distinct active sites of the surface antibodies, receptors for antigens (B-cells) and/or TCR producing the harmful anti-HIV-env antibodies (or similar harmful antibodies against the other viruses), the harmful auto-antibodies (as anti-HIV-gag or those in rheumatic diseases) or the harmful allergic antibodies, characterized in that these strong, localized precisely, specifically charges perturb the intercarbohydrate homologous hydrogen liaisons of the signalings of HIV and other viruses as well the functioning of the cell, producing these harmful antibodies for manufacture of medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ according Claim 6

Claim 10. The process of the functioning cycle of the cytoplasmic ribosomes for the folding (FKBP type of the proteins for the transporting "PKC" vesicle machinery) and the synthesis of all proteins at all ribosomes according claim 6 is characterized in that (1) During already the signal (in G1 or "G0" or the stocking signal at the G1 end), there is the constitution of the preproribosomes (nucleus, nucleole) from the proteins (with GR peptides), synthesized and folded on the active ribosomes (cytoplasm) (nuclear proteins as nucleolin or fibrillarin or ribosomal proteins as L5 or of the machinery of the transporting "PKC" vesicles /to be stocked/ or the steroid receptors that attach to the rRNA in nucleus /nucleole/); and these preproribosomes are activated (1st step!) by the special signal with the nuclear (serine or cysteine) proteinases (where the proteolysis of the N-part of the nucleolin, attached to the chromatin, is necessary for the pre-rRNA transcription) and they go to the cytoplasm where the 3'

Yufeng 18th Aug. 2004 1st sep.  
end p. 96 3rd sep: "aggregation in pathology  
cases" beginning p. 97 2nd sep:  
"as lead case on"

as Mad Cow or Jacob-Creutzfeldt) (this time, without signal already, but like during the signal!), due to the interactions with the forms of these proteins where the "Du-2T" is dissociated already and the carbohydrate chains (hiding) are free for already homologous intermolecular aggregation, facilitating already the dissociation (facilitated also generally!) the dissociation of the "Du-2T" of other molecules.

Claim 8. The large number of the different little proteins (peptides) (Du-2T-like = "Du-2T") according Claim 7 for the manufacture of the medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ against (1) the undesirable process of the complement activation; (2) the cell lysis; (3) the action of the particular membranous receptors; (4) the action of the parasites as the viruses and also bacteria, protozoans, mushrooms; (5) the creation of the dangerous priones (so called aggregated "scarpie" form) during the diseases as Mad Cow or Creutzfeldt-Jacob; (6) the protein aggregation in solutions (in blood included) characterized in that the simple introduction of these "Du-2T" proteins must stop the corresponding undesirable processes in preventing the dissociation of their native analogues where such dissociation would provoke the harmful signalling including the pathological diseases /(1)-(5)/ or the intermolecular glycoprotein aggregation in solution (6).

Claim 9. The well charged affine molecules (as antibodies) against the distinct HIV surface molecules (or those of other viruses and other parasites like bacteria or mushrooms or against distinct active sites of the surface antibodies, receptors for antigens (B-cells) and/or TCR producing the harmful anti-HIV-env antibodies (or similar harmful antibodies against the other viruses), the harmful auto-antibodies (as anti-HIV-gag or those in rheumatic diseases) or the harmful allergic antibodies, characterized in that these strong, localized precisely, specifically charges perturb the intercarbohydrate homologous hydrogen liaisons of the signalings of HIV and other viruses as well the functioning of the cell, producing these harmful antibodies for manufacture of medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ according Claim

6

Claim 10. The process of the functioning cycle of the cytoplasmic ribosomes for the folding (FKBP type of the proteins for the transporting "PKC" vesicle machinery) and the synthesis of all proteins at all ribosomes according claim 6 is characterized in that (1) During already the signal (in G1 or "G0" or the stocking signal at the G1 end), there is the constitution of the preproribosomes (nucleus, nucleole) from the proteins (with GR peptides), synthesized and folded on the active ribosomes (cytoplasm) (nuclear proteins as nucleolin or fibrillarin or ribosomal proteins as L5 or of the machinery of the transporting "PKC" vesicles /to be stocked/ or the steroid receptors that attach to the rRNA in nucleus /nucleole/); and these preproribosomes are activated (1st step!) by the special signal with the nuclear (serine or cysteine) proteinases (where the proteolysis of the N-part of the nucleolin, attached to the chromatin, is necessary for the pre-rRNA transcription) and they go to the cytoplasm where the 3'

Yufftage 18th May. 2004 End exp  
(end p. 97 3<sup>rd</sup> exp). Yufftage  
end p. 97 1st exp: "where the 3' "  
beginning p. 97 3rd exp: "as the car on Jacob- "



as Mad Cow or Jacob-Creutzfeldt) (this time, without signal already, but like during the signal!), due to the interactions with the forms of these proteins where the "Du-2T" is dissociated already and the carbohydrate chains (hiding) are free for already homologous intermolecular aggregation, facilitating already the dissociation (facilitated also generally!) the dissociation of the "Du-2T" of other molecules.

Claim 8. The large number of the different little proteins (peptides) (Du-2T-like = "Du-2T") according Claim 7 for the manufacture of the medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ against (1) the undesirable process of the complement activation; (2) the cell lysis; (3) the action of the particular membranous receptors; (4) the action of the parasites as the viruses and also bacteria, protozoans, mushrooms; (5) the creation of the dangerous priones (so called aggregated "scarpie" form) during the diseases as Mad Cow or Creutzfeldt-Jacob; (6) the protein aggregation in solutions (in blood included) characterized in that the simple introduction of these "Du-2T" proteins must stop the corresponding undesirable processes in preventing the dissociation of their native analogues where such dissociation would provoke the harmful signalling including the pathological diseases /(1)-(5)/ or the intermolecular glycoprotein aggregation in solution (6).

Claim 9. The well charged affine molecules (as antibodies) against the distinct HIV surface molecules (or those of other viruses and other parasites like bacteria or mushrooms or against distinct active sites of the surface antibodies, receptors for antigens (B-cells) and/or TCR producing the harmful anti-HIV-env antibodies (or similar harmful antibodies against the other viruses), the harmful auto-antibodies (as anti-HIV-gag or those in rheumatic diseases) or the harmful allergic antibodies, characterized in that these strong, localized precisely, specifically charges perturb the intercarbohydrate homologous hydrogen liaisons of the signalings of HIV and other viruses as well the functioning of the cell, producing these harmful antibodies for manufacture of medicaments /Art.52(4) EPO, Art.2(2) AT (Law 1970)/ according Claim

6

Claim 10. The process of the functioning cycle of the cytoplasmic ribosomes for the folding (FKBP type of the proteins for the transporting "PKC" vesicle machinery) and the synthesis of all proteins at all ribosomes according claim 6 is characterized in that (1) During already the signal (in G1 or "G0" or the stocking signal at the G1 end), there is the constitution of the preproribosomes (nucleus, nucleole) from the proteins (with GR peptides), synthesized and folded on the active ribosomes (cytoplasm) (nuclear proteins as nucleolin or fibrillarin or ribosomal proteins as L5 or of the machinery of the transporting "PKC" vesicles /to be stocked/ or the steroid receptors that attach to the rRNA in nucleus /nucleole/); and these preproribosomes are activated (1st step!) by the special signal with the nuclear (serine or cysteine) proteinases (where the proteolysis of the N-part of the nucleolin, attached to the chromatin, is necessary for the pre-rRNA transcription) and they go to the cytoplasm where the 3'

Yufeng 18th Aug. 2004 3rd exp.  
end p. 98 2nd exp: " to the cytoplasm  
where the 3' "  
beginning p. 98 1st exp: " the RNA part "

mRNA part serves as the guide for the cytoskeletal localisation; (2) These proribosomes (cytoplasm) are already activated definitively with the cathepsin L (CL) help that cuts (at GR peptides) the particular ribosomal proteins as L5 and the nuclear proteins as the nucleolin and fibrillarin (serving as fusible) and (CL) liberates also the stocked proteins of the "PKC" transporting vesicle machinery (necessary to start again the machinery of the proteins of the "PKC" transporting vesicle cycles without their synthesis) wherein these active ribosomes make the new synthesis and foldings with the help of the corresponding chaperons (FKBP type), attached yet from the nucleus, where, naturally, all ribosomes for all proteins, have the same cycles but without "traveling" proteins with the GR peptides where the same effective process of the protein synthesis of all proteins at the proribosomes (in reality, obtained from the cytoplasm) in vitro (attached for instance on the artificial surfaces) must be made with such CL activation: proribosomes→ribosomes.

Claim 11. The manufactured medicaments /Art.52(4) EPO, Art.2(2) AT law; Accord WIPO-AT/ against the state of the clinical death and coma as phosphatidylinositol-4,5-biphosphate or its derivatives including the lysoderivatives (with easier integration in PM with transport to the interior PM layer) and, like GTP-γS (less hydrolysable substratum also for vesicle transport) characterized in that all these substances help to avoid the process of the irreversible apoptosis of the cells of the brain and heart (original reason of the state of the clinical death and coma) according Claim 6.

Claim 12. The manufactured medicaments (hypnotics) /Art.52(4) EPO, Art.2(2) AT and Accord WIPO-AT) for the partial inhibition of the cycle of the "PKC" and synaptic ("PKC"-like) vesicles (like very deluted cyanate) for the sleep process are characterized in that they cut partially the cyclic system of the neurons of the superior brain (determining the cycle, establishing the conscience), functioning by the chaotic permanent cycles of the synaptic ("PKC"- like) transport vesicles according Claim 6(12).

1st exp. p. 98  
Yuffa

Yuffa (p. 97/4) 18/12/04  
end p. 97 3d exp.: go to the left plasma where the  
3' " beginning p. 98 2nd exp.: in RNA print  
series as the "

mRNA part serves as the guide for the cytoskeletal localisation; (2) These proribosomes (cytoplasm) are already activated definitively with the cathepsin L (CL) help that cuts (at GR peptides) the particular ribosomal proteins as L5 and the nuclear proteins as the nucleolin and fibrillarin (serving as fusible) and (CL) liberates also the stocked proteins of the "PKC" transporting vesicle machinery (necessary to start again the machinery of the proteins of the "PKC" transporting vesicle cycles without their synthesis) wherein these active ribosomes make the new synthesis and foldings with the help of the corresponding chaperons (FKBP type), attached yet from the nucleus, where, naturally, all ribosomes for all proteins, have the same cycles but without "traveling" proteins with the GR peptides where the same effective process of the protein synthesis of all proteins at the proribosomes (in reality, obtained from the cytoplasm) in vitro (attached for instance on the artificial surfaces) must be made with such CL activation: proribosomes→ribosomes.

Claim 11. The manufactured medicaments /Art.52(4) EPO, Art.2(2) AT law; Accord WIPO-AT/ against the state of the clinical death and coma as phosphatidylinositol-4,5-biphosphate or its derivatives including the lysoderivatives (with easier integration in PM with transport to the interior PM layer) and, like GTP-γS (less hydrolysable substratum also for vesicle transport) characterized in that all these substances help to avoid the process of the irreversible apoptosis of the cells of the brain and heart (original reason of the state of the clinical death and coma) according Claim 6.

Claim 12. The manufactured medicaments (hypnotics) /Art.52(4) EPO, Art.2(2) AT and Accord WIPO-AT) for the partial inhibition of the cycle of the "PKC" and synaptic ("PKC"-like) vesicles (like very deluted cyanate) for the sleep process are characterized in that they cut partially the cyclic system of the neurons of the superior brain (determining the cycle, establishing the conscience), functioning by the chaotic permanent cycles of the synaptic ("PKC"- like) transport vesicles according Claim 6(12).

Y. P. J. 2nd exp - 18th Aug. 04.,  
end of p. 8 1st exp: "Vehicles according to  
6/12" " beginning p. 98, 3rd exp: "in part  
part serves as the quine"

mRNA part serves as the guide for the cytoskeletal localisation; (2) These proribosomes (cytoplasm) are already activated definitively with the cathepsin L (CL) help that cuts (at GR peptides) the particular ribosomal proteins as L5 and the nuclear proteins as the nucleolin and fibrillarin (serving as fusible) and (CL) liberates also the stocked proteins of the "PKC" transporting vesicle machinery (necessary to start again the machinery of the proteins of the "PKC" transporting vesicle cycles without their synthesis) wherein these active ribosomes make the new synthesis and foldings with the help of the corresponding chaperons (FKBP type), attached yet from the nucleus, where, naturally, all ribosomes for all proteins, have the same cycles but without "traveling" proteins with the GR peptides where the same effective process of the protein synthesis of all proteins at the proribosomes (in reality, obtained from the cytoplasm) in vitro (attached for instance on the artificial surfaces) must be made with such CL activation: proribosomes→ribosomes.

Claim 11. The manufactured medicaments /Art.52(4) EPO, Art.2(2) AT law; Accord WIPO-AT/ against the state of the clinical death and coma as phosphatidylinositol-4,5-biphosphate or its derivatives including the lysoderivatives (with easier integration in PM with transport to the interior PM layer) and, like GTP-γS (less hydrolysable substratum also for vesicle transport) characterized in that all these substances help to avoid the process of the irreversible apoptosis of the cells of the brain and heart (original reason of the state of the clinical death and coma) according Claim 6.

Claim 12. The manufactured medicaments (hypnotics) /Art.52(4) EPO, Art.2(2) AT and Accord WIPO-AT) for the partial inhibition of the cycle of the "PKC" and synaptic ("PKC"-like) vesicles (like very deluted cyanate) for the sleep process are characterized in that they cut partially the cyclic system of the neurons of the superior brain (determining the cycle, establishing the conscience), functioning by the chaotic permanent cycles of the synaptic ("PKC"- like) transport vesicles according Claim 6(12).

Yup 18 Aug 2004 3u sup  
end p. 98: "d... spent various accounting clients  
6/12). " Legatory Form PCT/DB/308 : " PATENT COOPE-  
RATION Treaty WO 02/51233 PCT/EP02/02362  
From the International Bureau".

107505853

DT15 Rec'd PCT/PTO 24 AUG 2004



Abstract.

All AIDS principal mysteries are resolved. "One step" AIDS is successive contaminations (with low [anti-env]). Strong sole lethal animal doses are confirming. Mobility macrophage (mφ) receptors contaminate at 1st stage with nonproductive entry with nonintegrated and heterogenous (due to nef) HIV DNA and proteins and pseudoinfectious A particles. Such heterogeneity is obligatory for 2nd productive contamination with heterogenous anti-env, with integrated DNA and homologous proteins. Encephalites are due to moving into brain mφ due to locally liberated cyto and chemokines. Nongenetic factors are determining: at general persistent seronegativity (contact regularity) or absence of 2nd contamination due to different Fc receptor carbohydrates (babies before 3 months, chimpanzee). Minor genetic factors (as CCR5-2) only modify. AIDS in explaining all dangerous vaccinations. Carbohydrate origin of NK-cell mechanism. Artificial virus culture contaminations. HIV signalings are resolved with general laws of functional recognitions and foldings with help of Universalest "Du-2T"-like peptides and 2 prolyl-isomerases (coupled trans-cis transitions). Chaperons protect proteins against intercarbohydrate aggregations. Prione "scarpie" state is artificial dissociation of their "Du-2T". MHC and TRC allotypes are due to their carbohydrates. Hearts of any cell functioning: "PKC" transporting vesicle cycle and independent direct DNA activation. Apoptosis: irreversibility of preparation of next signal with stock exhaustions. Ribosome cycles. Key proprotein primary structures confirm above data. Consequences of profoundest bases: mφ mobility stopping against encephalites; charged antibodies eliminate viruses, cancer cells and harmful antibody clones (anti-viral, anti-auto); "Du-2T" eliminates viruses and "Mad Cow"; vaccines from homogenous viruses with one neutralizing epitope and correct virus titres; ribosomal protein synthesis; means against clinical death and coma; perfectest hypnotics.

Yefimov 18 Aug. 04 1st exp.  
end p. letter to Director of INPI."  
Yours sincerely, pp. E. De Hurcel.  
Director 1521 "  
beginning p. without the sup. "All AIDS principal"

Abstract.

All AIDS principal mysteries are resolved. "One step" AIDS is successive contaminations (with low [anti-env]). Strong sole lethal animal doses are confirming. Mobility macrophage (mφ) receptors contaminate at 1st stage with nonproductive entry with nonintegrated and heterogenous (due to nef) HIV DNA and proteins and pseudoinfectious A particles. Such heterogeneity is obligatory for 2nd productive contamination with heterogenous anti-env, with integrated DNA and homologous proteins. Encephalites are due to moving into brain mφ due to locally liberated cyto and chemokines. Nongenetic factors are determining: at general persistent seronegativity (contact regularity) or absence of 2nd contamination due to different Fc receptor carbohydrates (babies before 3 months, chimpanzee). Minor genetic factors (as CCR5-2) only modify. AIDS in explaining all dangerous vaccinations. Carbohydrate origin of NK-cell mechanism. Artificial virus culture contaminations. HIV signalings are resolved with general laws of functional recognitions and foldings with help of Universalest "Du-2T"-like peptides and 2 prolyl-isomerases (coupled trans-cis transitions). Chaperons protect proteins against intercarbohydrate aggregations. Prione "scarpie" state is artificial dissociation of their "Du-2T". MHC and TRC allotypes are due to their carbohydrates. Hearts of any cell functioning: "PKC" transporting vesicle cycle and independent direct DNA activation. Apoptosis: irreversibility of preparation of next signal with stock exhaustions. Ribosome cycles. Key proprotein primary structures confirm above data. Consequences of profoundest bases: mφ mobility stopping against encephalites; charged antibodies eliminate viruses, cancer cells and harmful antibody clones (anti-viral ,anti-auto); "Du-2T" eliminates viruses and "Mad Cow"; vaccines from homogenous viruses with one neutralizing epitope and correct virus titres; ribosomal protein synthesis; means against clinical death and coma; perfectest hypnotics.

Verlags 18 Aug. 2003 2nd exp.

end. p. 39 1st exp.: "perfekt hypochris"

beginning p. 99 3d exp.: "All AIDS principles mystica"

Abstract.

All AIDS principal mysteries are resolved. "One step" AIDS is successive contaminations (with low [anti-env]). Strong sole lethal animal doses are confirming. Mobility macrophage (m $\phi$ ) receptors contaminate at 1st stage with nonproductive entry with nonintegrated and heterogenous (due to nef) HIV DNA and proteins and pseudoinfectious A particles. Such heterogeneity is obligatory for 2nd productive contamination with heterogenous anti-env, with integrated DNA and homologous proteins. Encephalites are due to moving into brain m $\phi$  due to locally liberated cyto and chemokines. Nongenetic factors are determining: at general persistent seronegativity (contact regularity) or absence of 2nd contamination due to different Fc receptor carbohydrates (babies before 3 months, chimpanzee). Minor genetic factors (as CCR5-2) only modify. AIDS in explaining all dangerous vaccinations. Carbohydrate origin of NK-cell mechanism. Artificial virus culture contaminations. HIV signalings are resolved with general laws of functional recognitions and foldings with help of Universalest "Du-2T"-like peptides and 2 prolyl-isomerases (coupled trans-cis transitions). Chaperons protect proteins against intercarbohydrate aggregations. Prione "scarpie" state is artificial dissociation of their "Du-2T". MHC and TRC allotypes are due to their carbohydrates. Hearts of any cell functioning: "PKC" transporting vesicle cycle and independent direct DNA activation. Apoptosis: irreversibility of preparation of next signal with stock exhaustions. Ribosome cycles. Key proprotein primary structures confirm above data. Consequences of profoundest bases: m $\phi$  mobility stopping against encephalites; charged antibodies eliminate viruses, cancer cells and harmful antibody clones (anti-viral, anti-auto); "Du-2T" eliminates viruses and "Mad Cow"; vaccines from homogenous viruses with one neutralizing epitope and correct virus titres; ribosomal protein synthesis; means against clinical death and coma; perfectest hypnotics.

✓ (Raid) 18 August 2004 3d sup.  
end p. 2nd sup: "coma; perfect hypnosis"  
besonns p. PTO-2038 variant 1: "PTO-2038"  
(02-2003)

PTO/SB/09 (12-97)  
 Approved for use through 9/30/00. OMB 0651-0031  
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT CLAIMING SMALL ENTITY STATUS  
 (37 CFR 1.9(f) & 1.27(b))—INDEPENDENT INVENTOR**

Docket Number (Optional)

Applicant, Patentee, or Identifier: Y. Zagysky

Application or Patent No.: PCT/EP02/02302

Filed or Issued: 04 March 2002

Title: End of AIDS for general virology, based on profound science as protein foldings: safe vaccines,  
 universal antimicrobial means, mad cow end.

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.  
☒ the application identified above.  
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.  
☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

**Dr. Y. Zagysky (Dir. rech. Equ.)**

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of inventor

Signature of inventor

Signature of inventor

Date

Date

Date

July/August 18/12 August 2004  
Encl. of Form PTO/58/01 : "on O2LR attached  
hereby." Beginning copy of cheque (stapled)  
stapled to Form PTO-1390 : "Code: Agence  
Service générale groupe Paris Service AMONT  
Logistique unifiée."

107:505353

DT15 Rec'd PCT/PTO 24 AUG 2004



US

Annex US.III, page 2

PCT Applicant's Guide - Volume II - National Chapter - US

*Yuly Yulyagin 18th Aug. 04*  
*End of Form PTO-1390 is application to pending*  
*status - signature name registration number*  
*beginning form PTO/SB/09 in PTO/SB/09*  
*(12-97) Approved for use ...*

107 505 353

DT15 Rec'd PCT/PTO 24 AUG 2004

PTO/SB/01 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input type="checkbox"/> ust er mber <input type="text"/>		OR <input checked="" type="checkbox"/> Correspondence address below	
Name <b>Y.Zagyansky</b>			
Address <b>Entraide, 22 rue Ste Marthe</b>			
City <b>Paris</b>	State	ZIP <b>75010</b>	
Country <b>France</b>	Telephone	Fax <b>e-mails: zagyansky5.yuly@laposte.net and zagyansk@cyberport.tm.fr</b>	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.			
NAME OF SOLE OR FIRST INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any]) <b>Yuly</b>		Family Name or Surname <b>ZAGYANSKY</b>	
Inventor's Signature <i>Yuly Yulyagin</i>		Date <b>11th August 2004</b>	
Residence: City <b>Paris</b>	State	Country <b>France</b>	Citizenship <b>France</b>
Mailing Address <b>Entraide, 22 rue Ste Marthe</b>			
City <b>Paris</b>	State	ZIP <b>75010</b>	Country <b>France</b>
NAME OF SECOND INVENTOR		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
City	State	ZIP	Country
<input type="checkbox"/> Additional inventors or a legal representative are being named on the _____ supplemental sheet(s) PTO/SB/02A or 02LR attached hereto.			

PTO/SB/01 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**



Declaration  
Submitted  
With Initial  
Filing

OR



Declaration  
Submitted after Initial  
Filing (surcharge  
(37 CFR 1.16 (e))  
required)

Attorney Docket Number

First Named Inventor

ZAGYANSKY Yuly

COMPLETE IF KNOWN

Application Number

Filing Date

Art Unit

Examiner Name

I hereby declare that: ZAGYANSKY Yuly

Each inventor's residence, mailing address and citizenship are as stated below next to their name.

I believe the inventor(s) named below to be the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**"End of AIDS for general virology, based on profound science as protein foldings: safe vaccines,  
universal antimicrobial means, mad cow end"**

(Title of the Invention)

the specification of which



is attached hereto

OR



was filed on (MM/DD/YYYY)

03/04/2002

as United States Application Number or PCT International

Application Number

PCT/EP02/02302

and was amended on (MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (M DD/YYYY)	Priority Not claimed	Certified Co Yes	Attached? No
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Add on I for ignap caton umbe sa elst d on sup men al p iority ta sh et P SB/02B a ta ed here

[Page 1 of 2]

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

*Yuly Aguz* 18th August 2004

(1 January 2004)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**